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ventricular tachycardiaThe cardiac ryanodine receptor-Ca2+ release channel (RyR2) is an essential sarcoplasmic reticulum (SR)
transmembrane protein that plays a central role in excitation–contraction coupling (ECC) in cardiomyocytes.
Aberrant spontaneous, diastolic Ca2+ leak from the SR due to dysfunctional RyR2 contributes to the
formation of delayed after-depolarisations, which are thought to underlie the fatal arrhythmia that occurs in
both heart failure (HF) and in catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT is an
inherited disorder associated with mutations in either the RyR2 or a SR luminal protein, calsequestrin. RyR2
shows normal function at rest in CPVT but the RyR2 dysfunction is unmasked by physical exercise or
emotional stress, suggesting abnormal RyR2 activation as an underlying mechanism. Several potential
mechanisms have been advanced to explain the dysfunctional RyR2 observed in HF and CPVT, including
enhanced RyR2 phosphorylation status, altered RyR2 regulation at luminal/cytoplasmic sites and perturbed
RyR2 intra/inter-molecular interactions. This review considers RyR2 dysfunction in the context of the
structural and functional modulation of the channel, and potential therapeutic strategies to stabilise RyR2
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Ryanodine receptors (RyR) were ﬁrst observed in the 1970s, as
the so-called ‘foot’ structures in electron micrographs of striated
muscle, spanning the gap that is found at speciﬁc junctions between
the plasma membrane, or sarcolemma (SL), and the intracellular
sarcoplasmic reticulum (SR) membrane (Franzini-Armstrong, 1970;
Campbell et al., 1980). The RyR was subsequently isolated as angenic right ventricular cardiomyopath
phic ventricular tachycardia; CSQ, cals
Ca2+ channel; mAKAP, muscle speciﬁ
3; PKA, protein kinase A; PLB, phosph
, sarcoplasmic reticulum Ca2+ ATPase
: +44 29 2074 3500.
license.integral SRmembrane protein and its role as the Ca2+ release channel
demonstrated (Lai et al., 1988). The complementary DNA encoding
three distinct RyR channels was cloned and the corresponding gene
sequences obtained for three isoforms; RyR1 (Takeshima et al., 1989;
Zorzato et al., 1990), RyR2 (Nakai et al., 1990; Otsu et al., 1990;
Tunwell et al., 1996) and RyR3 (Hakamata et al., 1992). Through the
1980s and 1990s the central role of RyRs and the physiological
characteristics of excitation–contraction coupling (ECC) have beeny type 2; CaMKII, Ca2+/calmodulim-dependent protein kinase II; CICR, Ca2+ induced Ca2+
equestrin; DAD, delayedafter depolarisation; ECC, excitation–contraction coupling; FKBP12/
c A kinase anchoring protein; NCX, Na+/Ca2+ exchange protein; P-1 or P-2, phosphatase
oplamban; PP1, protein phosphatase 1; PP2A, protein phosphatase 2A; RyR1/2, ryanodine
; SL, sarcolemma; SR, sarcoplasmic reticulum; SOICR, store-overload-induced Ca2+ release.
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decade, discovery of numerous RyR2 gene mutations which underlie
the arrhythmogenesis that leads to sudden cardiac death (SCD) in
catecholaminergic polymorphic ventricular tachycardia (CPVT), have
added a new focus to the role of RyR2 dysfunction in cardiac disease
(Priori et al., 2001; George et al., 2007).
RyRs are expressed in many tissues but their most clearly deﬁned
pivotal role is in the regulation of ECC in muscle cells. In the heart, ECC
is the process by which an action potential (AP) at the surface of a
cardiomyocyte regulates the release of Ca2+ ions from SR Ca2+ stores
which then diffuse and bind to the myoﬁlaments to initiate
contraction (systole). The reuptake of Ca2+ into the SR Ca2+ store
causes relaxation (diastole), to complete the cycle comprising one
heart beat. The heart beat therefore is critically dependent on the
ﬁdelity of ECC, which in turn is exquisitely regulated by the signal
transmission occurring through the microdomain architecture at the
regions where the sarcolemma (SL) and its T-tubule invaginations
directly abut the junctional SR domains (Franzini-Armstrong et al.,
1999). These membranes are traversed by the critical membrane
pumps, ion exchangers and ion channels, which act synergistically
to maintain Ca2+ homeostasis and the AP. Control of cytoplasmic
free Ca2+ ion concentration is the key to the ECC process and this vital
parameter is regulated by a plethora of biochemical and protein
modulators and phosphorylation (Bers, 2002, 2004; Meissner, 2004).
Both physically and functionally, the RyR2 Ca2+ channels preside
at the heart of ECC acting as sentinels to the large SR Ca2+ store.
This review centres upon the role of the cardiac RyR2 isoform in
arrhythmia and SCD. RyR2 dysfunction manifested as tachyarrhyth-
mias is triggered by physical or emotional stress in CPVT patients and
similar symptoms causes SCD in ∼50% of heart failure (HF) patients.
These arrhythmias are believed to arise as a consequence of delayed
after-depolarisations (DADs) that are initiated by diastolic leak of
Ca2+ from dysfunctional RyR2. RyR2 function in the context of its
normal structural and functional regulation and its role in ECC will
be discussed in this review. The mechanism(s) by which RyR2
becomes dysfunctional, including abnormal phosphorylation, dis-
rupted interactionwith regulatory proteins and ions, or altered RyR2
domain interactions will be examined, and potential strategies for
therapeutic intervention will be considered.
2. Ryanodine receptor type-2 and excitation–contraction coupling
2.1. Junctional microdomain structure
Of vital importance to the reliability of ECC is the myocyte
intracellular architecture (Koh et al., 2006). The precise juxtaposition
of the SL and SR forms speciﬁc junctional microdomains, creating a
10–12 nM gap, known as the dyadic cleft, where the RyR2 cytoplasmic
region resides, and its transmembrane region spans the SR membrane
to immerse the ‘luminal’ portion into the SR Ca2+ store (Franzini-
Armstrong et al., 1999). Traversing the SL is the L-type Ca2+ channel
(LCC) and the Na+/Ca2+ exchange protein (NCX). Although in cardiac
muscle there is no allosteric contact between these proteins they are
co-ordinately regulated via the changing concentrations of Ca2+, Na+
and K+ within the dyadic cleft (Stern, 1992; Niggli & Lipp, 1993;
Greenstein & Winslow, 2002) (Fig. 1). Regular 2D arrays of RyR2 are
found at the junctional SR with clusters comprising 70–250 RyR2
particles (Chen-Izu et al., 2006; Soeller et al., 2007) depending upon
species (Franzini-Armstrong et al., 1999), with faster heart rate
corresponding to greater numbers within an array. The RyR together
with the LCC (and NCX and other ion channels) form a unit referred to
as a ‘couplon’ (Stern et al., 1999). Although the term couplon describes
the physical unit of a junctional domain, the functional Ca2+ release
unit may only be a fraction of the RyR array and be deﬁned by
physiological and experimental conditions (see Section 2.2.1 on Ca2+
sparks).2.2. Regulation of ryanodine receptor type-2 by Ca2+
Throughout the ECC cycle, the RyR2 is exposed to continually
changing Ca2+ concentrations, both dyadic, luminal and within the
transmembrane pore. These changes are critical to RyR2 regulation
and numerous studies have modelled the precise modal gating of the
RyR by Ca2+. These aspects are beyond the scope of this review, but
have been given comprehensive treatment by others (Rice et al., 1999;
Stern et al., 1999; Soeller & Cannell, 2004; Koh et al., 2006). To
measure the dynamics of gating, single RyR channels are inserted into
planar lipid bilayers separating two chambers; the cis chamber —
corresponding to the cytoplasmic face of RyR, and trans chamber
corresponding to the SR luminal face. Brieﬂy, this method involves
measuring the current ﬂowing between the two chambers, carried by
ion ﬂuxes occurring through the RyR pore. Ryanodine binding studies
(Meissner et al., 1988), based on binding of the plant alkaloid,
ryanodine, which occurs only to the open channel (Fleischer et al.,
1985), can also be used as an indirect measure of the RyR channel
open probability (Po), but unlike single channel studies only gives a
snapshot of the steady state (Valdivia et al., 1995).
2.2.1. Ca2+ sparks
The Ca2+-induced Ca2+ release (CICR) phenomenon was ﬁrst
proposed as an ECC mechanism in skinned muscle ﬁbres (Fabiato &
Fabiato, 1979). Subsequently, ﬂuo-3 confocal microscopy with intact
cardiac myocytes enabled observation of spontaneous Ca2+ ‘sparks’,
which result from simultaneous opening of a group of RyR2s (Cheng
et al., 1993). A Ca2+ spark can originate from trigger Ca2+ (a ‘sparklet’)
entering through one LCC (the ICa current) to activate a cluster of
opposing RyR2 molecules to discharge SR store Ca2+ (Lopez-Lopez
et al., 1995; Wang et al., 2001). A study of the quantal nature of Ca2+
sparks suggested that normally a few RyR2s were recruited (4–6)
although 12% of spark events emanated from a single RyR2 channel
opening (Wang et al., 2004). Other studies have estimated greater
numbers of RyR2molecules in a spark cluster; 15–30 (Izu et al., 2001),
10 (Lukyanenko et al., 2000),18–25 (Lukyanenko et al., 2007) and 35–
43 (Mejia-Alvarez et al., 1999). It is also proposed that, in practice a
group of LCC may gate a cluster of underlying RyR2s in order to ensure
that the probability of a spark from that cluster is sufﬁciently high to
ﬁre reliably with each AP (Inoue & Bridge, 2003). The relationship
between the LCC Ca2+ current and the quantity of Ca2+ released from
Ca2+ stores is called ‘Ca2+ gain’ and deﬁned as the ratio between total
Ca2+ ﬂux through RyR relative to that through the LCC. The
parameters which regulate this process are complex, involving their
physical relationship (dyadic cleft), innate regulation of the individual
RyR and LCC channels and the numbers activated (Altamirano & Bers,
2007; Wier, 2007).
Many individual sparks coalesce to give the characteristic Ca2+
wave/transient, a phenomenon termed the local control or ‘cluster
bomb’ hypothesis (Stern, 1992; Rios & Stern, 1997; Williams, 1997;
Cannell & Soeller, 1998). The extent of recruitment of RyR2s to a spark
depend upon both the mechanisms initiating the spark and the
regulatory inﬂuences modulating RyR activity, including allosteric
interactions of RyRs with their neighbours (Yin & Lai, 2000; Yin et al.,
2005a,b) and the disposition of other proteins (Rice et al., 1999). The
mechanism of simultaneous activation of the RyR2molecules within a
cluster to produce a spark is unknown. Stochastic gating theory
suggests that each RyR molecule activates and closes independently
(Klein et al., 1996; Rios & Stern, 1997). However, it has been observed
that two or more RyR channels inserted into a bilayer can either gate
individually (stochastically) or synchronously (coupled), although the
latter was observed only in the presence of the modulator, FK506
binding protein (FKBP12 or 12.6). Coupled activation would require
the physical interaction of adjacent RyR molecules (see Section 2.5).
Extensive RyR 2D arrays, making up a couplon in situ (Franzini-
Armstrong et al., 2005; Chen-Izu et al., 2006), can also be formed by
Fig. 1.Movement of Ca2+ between the SR Ca2+ store, the dyadic space and the extracellular space during ECC. During diastole the Ca2+ concentration in the dyadic cleft is b10−7 M,
intracellular Ca2+ is contained within the SR, and the RyR2 channel (in grey) is closed. As the AP sweeps across the SL (‘Activation’), the voltage-sensitive LCC is activated to allow the
entry of trigger Ca2+ (∼10% of that required for contraction enters the dyadic space). The rapid rise in local Ca2+ concentration activates RyR2 (‘RyR2 Opens’). The Ca2+ concentration
within the dyadic space rises further as Ca2+ is released from the SR Ca2+ store, which activates the NCX and inhibits LCC. The released Ca2+ diffuses into the cytoplasm to deinhibit
the contractile proteins and myoﬁlament contraction occurs. Ca2+ is pumped back into the SR by SERCA and out of the cell via NCX, thus Ca2+ homeostasis is restored. RyR2 closes
during systole and this could be mediated by either reduced Ca2+ concentrations in the SR lumen, inhibitory action of dyadic cleft Ca2+ concentrations or by inherent RyR2
mechanisms making it unavailable for stimulation by Ca2+. These events are further discussed in the text.
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context of ECC, the structural basis of Ca2+ sparks and their genesis is
incompletely understood (Soeller et al., 2007). 2D arrays of RyR2
could theoretically allow a large population of receptors to be simul-
taneously switched on, or off, by a tiny change in ligand concentration
(Liang et al., 2007; Yin et al., 2008). However, considerations of modal
channel gating and Ca2+ spark generation involving only a small
proportion of RyR molecules within a couplon, raises issues regarding
the precise role of RyR oligomeric interaction in ECC (Stern et al., 1999;
Fill & Copello, 2002).
The feed-forward and feed-back mechanisms of ECC are relatively
well deﬁned with one exception — RyR2 closure (Stern & Cheng,
2004). CICR is a process which is theoretically self-perpetuating
(although clearly not so in practice) and thereby considered to be
inherently unstable. The activated RyR2 must also close to maintain
the ﬁdelity of the heartbeat, but the underlyingmechanism(s) leading
to closure have been difﬁcult to demonstrate experimentally or
deﬁnitively. With respect to Ca2+ spark termination, the rise time of a
spark decreases proportionately with the number of participating
RyR2s and it has been suggested that this is due either to inhibitory
feed-back by the dyadic Ca2+ concentration overriding regenerative
CICR (Wang et al., 2004), or to the concomitant decrease in SR luminal
Ca2+ underlying the spark site (Brochet et al., 2005; Huertas & Smith,
2007). However, there may be other determinants for CICR termina-
tion, such as intrinsic changes occurring within the RyR2 such as
inactivation, adaptation (Cheng et al., 1995; Sitsapesan et al., 1995;Laver & Lamb, 1998; Fill et al., 2000) and stochastic attrition (Stern
et al., 1999) or allostery between RyRs (Yin et al., 2008).
2.2.2. Cytoplasmic Ca2+ (dyadic cleft)
Single channel recordings and ryanodine binding experiments
have shown that RyR2 open probability, Po, exhibits a biphasic res-
ponse to cytoplasmic Ca2+ concentration, with an activation threshold
of ∼10−8–10−7 and maximal activation at 10−6–10−5 M, that
declines with increasing concentrations and maximal inhibition
occurring at ∼10−2 M Ca2+ (Meissner, 2002). Maximal activation is
observed in the presence of ∼1 mM ATP, in cell free systems, while
physiological concentrations of 1 mM Mg2+ inhibit Po (Meissner &
Henderson, 1987; Holmberg & Williams, 1990; Tinker & Williams,
1992), either by competing for Ca2+ activation sites, low afﬁnity
inhibition sites (Laver et al., 1997) or sites in the Ca2+ pore (Valdivia
et al., 1995). Ca2+ ions that enter the cell upon LCC activation provides
∼10% of the Ca2+ available for contraction (Bers, 2002).
The small volume of the dyadic cleft and the close proximity of the
junctional RyR to LCC results in a rapid local increase in Ca2+
concentration, activating RyR2 and evoking systolic Ca2+ release from
the SR Ca2+ store. Models suggest that the dyadic cleft Ca2+ con-
centration can reach 1 mM and the estimated number of Ca2+ ions
required to achieve this concentration within its deﬁned dimensions
(whichmaybe species-dependent) is 10–100 (Tanskanen et al., 2007) or
1000 (Koh et al., 2006) with only 1–2 remaining in diastole (Koh et al.,
2006). The concentrations of Mg2+ and ATP, which regulate RyR2 and
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changes within the dyad environment (Valent et al., 2007). The released
Ca2+diffuses swiftly to themyoﬁlaments,whichare in close proximity to
the SR Ca2+ ATPase (SERCA) pumps and their regulatory protein
phospholamban (PLB) situated on the longitudinal SR. SERCA reseque-
sters the released Ca2+ into the SR Ca2+ store. The raised Ca2+ in the
dyadic cleft has a retrograde inhibitory action on LCC and also activates
the NCX, which effectively drives Ca2+ out of the cell (Bers, 2002). Thus,
the Ca2+ store release by RyR2 is balanced by reuptake through SERCA,
and Ca2+ inﬂux through LCC is balanced by efﬂux via the NCX. These
coordinated processes of Ca2+ ionmovement provide a counter balance
for each other in order tomaintain a steady state (Diaz et al., 2005), Fig.1.
2.2.3. Luminal Ca2+
When CICR was proposed as a RyR activation mechanism it was
recognised fromthe requirement for a threshold, that the amountof Ca2+
within the SR exerted a regulatory inﬂuence on its release (Fabiato &
Fabiato, 1979). Single channel experiments have conﬁrmed that the
greater the luminal Ca2+ concentration, the more responsive RyR2
becomes to activator Ca2+ concentration (in the presence of ATP)
(Lukyanenko et al., 1996; Sitsapesan &Williams, 1997; Gyorke & Gyorke,
1998), and a speciﬁc Ca2+-sensitive luminal regulation site has been
proposed (Laver, 2007). This phenomenon has also been observed in
cardiomyocytes, where for a given Ca2+ trigger, the SR Ca2+ release via
RyR2 is proportional to the SR Ca2+ concentration (Han et al., 1994;
Janczewski et al., 1995; Satoh et al., 1997) and spark frequency is also
increased with SR Ca2+ load (Satoh et al., 1997). Phosphorylation may
also play a role in increasing the sensitivity of RyR2 to luminal Ca2+ (Xiao
et al., 2007a) — see Section 2.4.1.
2.2.4. Calsequestrin, triadin and junctin
It has been proposed that the luminal RyR2 accessory proteins,
calsequestrin (CSQ), triadin and junctin, directly regulate the RyR2
channel sensitivity to luminal Ca2+ (Gyorke et al., 2004), as part of a
process termed luminal Ca2+-dependent deactivation (Terentyev
et al., 2002; Shannon et al., 2003). CSQ has a low afﬁnity for Ca2+
(∼600 µM) and each molecule can bind about 40 Ca2+ ions, which
cause a major conformational change in the protein (Mitchell et al.,
1988). Since Ca2+ release rises steeply with SR Ca2+ concentration,
CSQ may therefore play a role in Ca2+ buffering within the SR to
regulate the luminal free Ca2+ concentration (Shannon et al., 2000).
In addition, a role for CSQ as the RyR2 luminal Ca2+ sensor is also
proposed (Beard et al., 2005). The two proteins, triadin (Terentyev
et al., 2007) and junctin have luminal and transmembrane regions
(Zhang et al., 1997) and form into a complex with CSQ that appears to
inhibit RyR Po when Ca2+ concentration is low and this inhibition is
relieved as Ca2+ rises (Gyorke et al., 2004).
In adult ventricular rat myocytes, the functional size of the SR Ca2+
store was regulated by the amount of CSQ expressed (Terentyev et al.,
2003; Miller et al., 2005). In CSQ2 knock-out mice the volume of the SR
was doubled, demonstrating a physical compensation for CSQ2 ablation,
with expression of junctin and triadin also suppressed via an unknown
mechanism (Knollmann et al., 2006). Field-stimulated CSQ2-null
myocytes showed a decrease in time to peak Ca2+ release and
concomitant slowing of the time to 50% peak contraction. In unstimu-
lated myocytes, there was an increase in spontaneous Ca2+ sparks
(Knollmann et al., 2006) suggesting that the CSQ/triadin/junction
complex (Terentyev et al., 2003; Gyorke et al., 2004)might act to reduce
the Po of RyR2 at high Ca2+ load, but that RyR2 could also independently
sense Ca2+ load in the absence of the CSQ (Knollmann et al., 2006). In
addition, at low free Ca2+ concentrations the CSQ/triadin/junction
complex may be inhibiting RyR2 directly. Luminal Ca2+-dependent
deactivation has been proposed to provide amechanism for termination
of CICR (Gyorke & Terentyev, 2008). In support of this mechanism one
study has demonstrated, with sufﬁcient spatial and temporal resolution,
a decrease in luminal Ca2+ concentration (termed a Ca2+ ‘blink’),immediately beneath a RyR2 cluster during Ca2+ release from the SR,
which complemented a Ca2+ spark in the dyadic space (Brochet et al.,
2005).
2.3. Ryanodine receptor type-2 and the
generation of delayed after depolarisations
As well as the maintenance of Ca2+ homeostasis, the dyadic cleft is
vitally important to maintaining the electrical coupling which
regulates the heart-beat. In response to the AP, LCC is activated and
Ca2+ moves down the diffusion gradient into the dyadic cleft. For the
heart to relax the cell must repolarise. The LCC is sensitive to
retrograde inhibition by the rate and quantity of Ca2+ released by
RyR2 from the SR Ca2+ store and is also shut off by repolarisation of
the membrane by K+ channels (Richard et al., 2006). The Na+/K+
ATPase and NCX also play a role in this process, thus dovetailing the
electrogenic exchange with the maintenance of Ca2+ homeostasis
(Scoote & Williams, 2002; Pogwizd & Bers, 2004).
The type of arrhythmia which is the topic of this review involves
DADs which originate from within the myocyte and are blocked by
ryanodine (Marban et al., 1986; Song & Belardinelli,1994). These DADs
are caused by an inappropriately timed, spontaneous efﬂux of Ca2+
escaping the SR via the RyR2, termed a diastolic ‘leak’ (see Fig. 2). Note
that this is not the SR Ca2+ ﬂux that can be measured through reversal
of SERCA (Shannon et al., 2000) which has also been called diastolic
Ca2+ leak. If sufﬁcient Ca2+ is released into the dyadic space after
repolarisation but before the next AP, this will cause NCX to operate in
reverse (Na+ entry mode). This NCX activity leads to a depolarisation
which invokes the transient inward current — Iti (Venetucci et al.,
2007), that propagates to adjacent cells provoking an arrhythmia (for
amore detailed consideration see Scoote &Williams, 2002; Pogwizd &
Bers, 2004).
DADs can also be caused by SR Ca2+ store overload (Diaz et al.,
2004) and by the action of glycosides on the Na+/K+ ATPase (Rosen &
Danilo, 1980; Wier & Hess, 1984; Hauptman & Kelly, 1999). Increasing
the Po of RyR2 by addition of low caffeine concentrations alone
increases Ca2+ spark frequency in cardiomyocytes, but these are of
low amplitude due to decrease in SR Ca2+ stores (Trafford et al., 2000),
and do not produce DADs unless the myocytes are subjected to β-
adrenergic stimulation (Venetucci et al., 2007). Caffeine also produces
DADs in ventricular wedge preparations (Nam et al., 2005) under
similar circumstances. Thus, increasing RyR2 Po per se is not
arrhythmic, since this would be traded against decreased store
content (Aizawa et al., 2007; Venetucci et al., 2007). The effect of β-
adrenergic stimulation is to increase SR Ca2+ store concentrations via
phosphorylation of PLB and upregulation of SERCA. However,
phosphorylation may also alter RyR2 channel gating through direct
phosphorylation of the RyR2 (see Section 2.4) or through regulation
by luminal Ca2+, thus suggesting that perturbing both autoregulation
of RyR2 and Ca2+ homeostasis may be necessary to provoke DADs
(Niggli, 2007). Conversely, DADs triggered by such a combined
perturbation could be reduced by tetracaine, which reduces the Po
of RyR2 (Venetucci et al., 2006).
2.4. Phosphorylation/dephosphorylation
Kinase/phosphatase signalling complexes have been described for
three cardiac ion channels; LCC, K+ channels and RyR2, created by the
association of phosphatases and kinases with anchoring proteins held
together by leucine zipper protein/protein interaction domains (Marx
et al., 2001b; Hulme et al., 2004). These complexes enable the
compartmentalisation of protein kinase A (PKA), protein phosphatase 1
(PPI), protein phosphatase 2A (PP2A) (Marx et al., 2001b), CaMKII (Ai
et al., 2005), and phosphodiesterase 4D3 (PDE4D3) (Dodge et al., 2001),
so that phosphorylation/dephosphorylation can be spatially and tempo-
rally regulated (Hulme et al., 2004). For the RyR2 complex, PKA and
Fig. 2. Relationship between diastolic RyR2 Ca2+ leak, mechanisms of RyR2 dysfunction and the generation of DADs. A number of causes of diastolic leak from dysfunctional RyR2 are
proposed for HF. These include ‘hyperphosphorylation’ of RyR2 and altered sensitivity to Ca2+. In CPVT mutations, perturbation of RyR2 domain interactions, and increased RyR2
sensitivity to luminal Ca2+, have been proposed. The consequent increase in released Ca2+ is thought to trigger the NCX to cause an inﬂux of Na+ that leads to a compensatory
transient DAD. See the text for further explanation.
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speciﬁc A-kinase anchoring protein (mAKAP) (Dodge et al., 2001),
and PP1 and PP2A associate with RyR2 via the anchoring proteins
spinophilin andPR130, respectively (Marxet al., 2001b) (see Fig. 3). RyR2
currently has three well-deﬁned phosphorylation sites, S2030 (Xiao
et al., 2005), S2809 and S2815 although there may be others (Rodriguez
et al., 2003). S2030 and S2809 are phosphorylated by PKA, and S2809
(Witcheret al.,1991;Marxet al., 2000b;Rodriguez et al., 2003) andS2815
by Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Witcher
et al., 1991; Wehrens et al., 2004b).
2.4.1. Phosphorylation by protein kinase A
The ﬂight-or-ﬁght response, driven by adrenergic stimulation of
cardiac β-adrenoreceptors raises intra-myocyte cAMP, which causes
PKA activation. PKA can phosphorylate and co-ordinately regulate
(either directly, or indirectly via a regulatory protein) all of the major
components of the ECC cycle (see Bers, 2002 for review, also Fig. 3).
This has the effect of increasing the heart rate and the force of
contraction (Lakatta, 2004).
The effect of phosphorylation on RyR2 activity in myocytes has
been difﬁcult to deﬁne experimentally. PKA phosphorylation has been
reported to increase the synchronicity of Ca2+ sparks (Song et al.,
2001) and RyR2 coupling ﬁdelity (probability of activating a release
site; Shen, 2006), increase the amplitude of Ca2+ spark width and
duration (Tanaka et al., 1997; Song et al., 2001; Shen, 2006), or to have
little effect (Hussain & Orchard, 1997). Ca2+ gain or fractional Ca2+
release, a measure of Ca2+ release/ICa, is similarly reported to be
enhanced (Hussain & Orchard, 1997), unchanged (Ginsburg & Bers,2004) or reduced by phosphorylation (Song et al., 2001). Upregulation
of Ca2+ release could occur as a result of (i) phosphorylation of LCC
enhancing ICa (Yue et al., 1990; Herzig et al., 1993; Chen-Izu et al.,
2000), (ii) phosphorylation of PLB at S16 or T17 (deinhibiting and
upregulating SERCA (Li et al., 2000)) thus increasing SR store Ca2+,
(iii) an increased sensitivity of phosphorylated RyR2 to activator Ca2+
concentrations (Marx et al., 2000b), or (iv) an increased sensitivity to
luminal Ca2+ concentrations (Xiao et al., 2007a). Experiments that
manipulate the Ca2+ store using thapsigargin (SERCA inhibitor) have
shown Ca2+ release to be governed by ICa (Hussain & Orchard, 1997)
such that release is graded by increased trigger Ca2+. Others have
suggested that the size of the Ca2+ store governs increased Ca2+
release. PLB knock-out or PLB-DM (double-mutant) knock-in mice
with S16A/T17A substitutions, in which the SR Ca2+ store would
remain constant, have shown that in permeabilised myocytes (no ICa),
isoprenaline did not alter Ca2+ sparks (Li et al., 2002). A second study
with the PLB-DM mice showed that fractional Ca2+ release over a
wide range of ICa and SR Ca2+ store concentrations was unchanged by
isoprenaline, suggesting that although the overall balance of inﬂux
and release was maintained, Ca2+ release was turned on and off more
quickly with isoprenaline treatment and these faster kinetics were
attributed to the effect of RyR2 phosphorylation (Ginsburg & Bers,
2004).
Single channel studies of RyR2 channel gating have shown that
PKA phosphorylation can overcome Mg2+ block (Hain et al., 1995)
rendering the channel active at physiological Mg2+ concentrations
(∼1mM), while ATP no longer modiﬁed channel gating though Po was
increased (Valdivia et al., 1995; Uehara et al., 2002). PKA
Fig. 3. Regulation of ECC by phosphorylation/dephosphorylation. In response to β-adrenergic receptor stimulation by circulating catecholamines, adenyl cylase (AC) is activated and
the diffusible second messenger cAMP is produced. This activates PKA which is associated with, and phosphorylates, a large number of proteins (NCX, LCC, RyR2 and PLB). PKA
interacts with these target often via the scaffolding protein, AKAP. The key PKA targets are indicated by dashed lines. The action of PKA increases the activity of these target proteins
and augments the rate of Ca2+ cycling in ECC, leading to an elevated heart rate. CaMKII is activated by Ca2+ (via calmodulin; CM) and can also activate key proteins in ECC and these
are indicated by #. Protein phosphatases down-regulate ECC by dephosphorylation of the kinase target proteins (indicated by dotted lines), and can in turn be regulated by P-I. The
major directions of Ca2+ ion ‘movement’ and the additional regulation of ECC by Ca2+/CM are indicated by the solid lines. The lower left inset schematically depicts the RyR2
macromolecular complex that has been proposed to exist by Marks and colleagues, illustrating its association with those proteins concerned with phosphorylation/
dephosphorylation. Several other cytosolic proteins are known to interact with RyR2, although their precise functional role remains to be clariﬁed. The inset also indicates the mouse
RyR2 amino acid number of the three known serine phosphorylation sites that are associated with PKA (⁎) and CaMKII (#) action. Further explanation is given in the text.
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opening became more responsive to a stepped increase in Ca2+,
although the rate of channel adaptation was also increased (Valdivia
et al., 1995). This might result in lower steady state activity which
manifests as a decrease in ryanodine binding (Valdivia et al., 1995),
consistent with a study in cardiomyocytes demonstrating an
increased rate of channel opening matched by an increased rate of
termination in the presence of isoprenaline (Ginsburg & Bers, 2004).
Analysis of sheep RyR2 suggests that in normal conditions there is
already a substantial level of phosphorylation (S2809 phosphorylated
to 75%) (Carter et al., 2006). Stoichiometric phosphorylation of S2809
with PKA resulted in increased conductance and increased Po.
However, since PKA can phosphorylate RyR2 at two sites, S2809 and
S2030, PKA-dependent phosphorylation of S2030 may speciﬁcally be
responsible for the observed functional effects on single RyR2 channels
(Xiao et al., 2005). Interestingly, RyR2dephosphorylation also caused a
modest increase in Po (Carter et al., 2006). Others have reported that
PKA phosphorylation increased Po and produced subconductance
states (presumably related to the loss of endogenous FKBP12.6, see HF
in Section 4.1.2.2.) and it was proposed that phosphorylation increased
the Ca2+ sensitivity of activation (Marx et al., 2000b). However,
another phosphorylation study observed no change in activation bycytosolic (cis) Ca2+ on single channel analysis, but speciﬁcally linked
S2030 phosphorylation to an enhanced response of RyR2 to luminal
(trans) Ca2+ (Xiao et al., 2007a).2.4.2. Phosphorylation by Ca2+-calmodulin kinase II
A second protein kinase, CaMKII (the δC isoform in heart (Zhang et
al., 2007)) is activated by [Ca2+]i possibly at high cellular Ca2+ loads
(MacQuaide et al., 2007) and is associated with the phosphorylation
of many of the same ECC proteins as PKA. Phosphorylation of LCC can
enhance ICa (Wu et al., 2004). Experimentally, phosphorylation of PLB
at T17 occurs in a frequency-dependent manner in electrically-paced
myocytes and the increased cytosolic Ca2+ causes autophosphoryla-
tion of CaMKII, which is proposed to sustain phosphorylation levels of
PLB T17 between beats (Hagemann et al., 2000) thus increasing both
the rate of SERCA and SR store Ca2+ levels (Hagemann et al., 2000). In
situ increased frequency of beating results from the activation of PKA
through β-adrenergic stimulation, which in turn increases cytosolic
Ca2+ hence activating CaMKII. Thus, distinguishing their precise roles
and the relative importance of phosphorylation of RyR2 by PKA and
CaMKII is problematic (Bers, 2006; Sipido, 2007; Yamaguchi &
Meissner, 2007).
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lated the CaMKII pathway and both RyR2 S2808 (PKA) and S2815 (the
phosphorylation site for CAMKII (Witcher et al., 1991; Wehrens et al.,
2004b)) were phosphorylated (Ferrero et al., 2007). In another study,
the use of speciﬁc CaMKII inhibitors or using forskolin to bypass β-
adrenergic stimulation and activating adenyl cyclase directly, was
consistent with increased diastolic Ca2+ leak being mediated by
CaMKII but not PKA (Curran et al., 2007). Two studies have used the
CaMKII inhibitory peptide AIP, to reduce the activity of endogenous
CaMKII. In rabbit cardiomyocytes, AIP caused decreased ryanodine
binding and Ca2+ spark activity (Currie & Smith, 1999). Mice
expressing a SR targeted AIP showed a 62% reduction in RyR2 S2815
phosphorylation and decreases in SR Ca2+ release via RyR, SR Ca2+
uptake (SERCA activity) and Ca2+ entry via LCC (Picht et al., 2007).
Both these studies therefore support the view that endogenous
CAMKII activity increases RyR Po, SR Ca2+ release via PLB regulation of
SERCA and LCC activity. However, Wu et al. used both constitutively
active CAMKII and an inhibitory peptide AC3-I in ventricular myocytes
to show that although LCC activity is increased, RyR2 activity is
reduced by CaMKII addition (Wu et al., 2001). Using a viral expression
system the effects of constitutively active CaMKII, WT and inactive
CaMKII were compared in rat myocytes. PLB phosphorylation was
increased by the constitutively active isoform and the global decay of
the Ca2+ transient was increased and store Ca2+ rose, consistent with
upregulation of SERCA. However Ca2+ sparks and Ca2+ transients
were suppressed, indicative of a decrease in spontaneous Ca2+ release
and a negative regulation of RyR2 activity. This was proposed as a
mechanism that restrained the positive feedback effects of raised Ca2+
and thus stabilised ECC (Yang et al., 2007).
Single channel studies of the effects of CaMKII phosphorylation of
RyR2 also give inconsistent results. Some reported observing similar
characteristics to PKA phosphorylation, in that CaMKII phosphoryla-
tion was able to reverse Mg2+ inhibition in single channel studies,
however, these showed that Po was decreased overall (Wang & Best,
1992; Hain et al., 1995; Lokuta et al., 1995) and ryanodine binding
studies also revealed a reduced Po (Lokuta et al., 1995). Others found
that CaMKII phosphorylation increases Po of RyR2 which is speciﬁcally
related to the S2815 phosphorylation site (Wehrens et al., 2004b).
Thus, although phosphorylation is generally reported to upregu-
late the ECC cycle there is a disconcerting lack of consistency in the
results of many studies, particularly concerning the mechanism of
action of phosphorylation on RyR2 function and whether effects are
mediated by PKA or CaMKII (Bers, 2006; Sipido, 2007; Yamaguchi &
Meissner, 2007).
2.4.3. Dephosphorylation
To counter up-regulation by phosphorylation are the equally
important processes which return ECC to the status quo ante by
dephosphorylating the component proteins when the stimulus
diminishes. Dephosphorylation is carried out by protein phosphatases
and isoforms PP1, PP2A (Neumann et al., 1993) and calcineurin are all
expressed in heart (Jones et al., 2003). Binding domains on RyR2 have
been identiﬁed for PP1 and PP2A (via scaffolding proteins) (Marx
et al., 2001b). The protein phosphatases PP1 and PP2A also affect
SERCA activity by dephosphorylation of PLB (MacDougall et al., 1991).
To add a further layer of complexity PPI can itself be phosphorylated
by PKA, which inhibits its action and dephosphorylation of PP1 (by
PP2A) can be inhibited by the action of phosphatase-inhibitors-1 or -2
protein (P-1/2) (Endo et al., 1996), Fig. 3.
2.5. Regulation of ryanodine receptor type-2 by FKBP12.6
FKBP12 modulates RyR1 and the FKBP12.6 isoformmodulates RyR2.
These12 kDaproteins are thought to be potent and important regulators
of RyR function. They bind with high afﬁnity in both the open or closed
state of the channel although the afﬁnity is greater when the channel isclosed (Jones et al., 2005b) and indeed interaction with the FKBP12
protein was ﬁrst identiﬁed by its persistent co-puriﬁcation with RyR1
channels (Collins, 1991; Jayaraman et al., 1992). One FKBP12 interacts
with one RyR1 subunit (Jayaraman et al., 1992; Timerman et al., 1995)
and topological analysis has shown four FKBP12 molecules bound sym-
metrically proximal to the N-terminus (Wagenknecht et al., 1997). The
binding site on RyR was originally thought to be in the central domain
around leucine-proline site 2407–2520 (RyR1) (Cameron et al.,1997) or
2361–2496 (RyR2) (Marx et al., 2000), which are homologous to the
proposed binding region on the inositol (1,4,5) tris phosphate receptor
(Cameron et al.,1997). Studiesmutating key residues in this region have
shown these to decrease FKBP12/12.6 binding (Bultynck et al., 2001b;
Gaburjakova et al., 2001; Avila et al., 2003; Van Acker et al., 2004). The
use of limited proteolysis of RyR2, mapped the 2756–2803 epitope —
recognised by the m34C antibody, to within a 45 kDa FKBP12.6 binding
fragment (Bultynck et al., 2001a). One study showed binding to the
2341–2356 RyR2 site using the yeast-2-hybrid technique (Marx et al.,
2000) although another study failed to pick out this region using the
same technique or recombinant expression of overlapping RyR2
fragments and FKBP12.6 pull-down assays (Zissimopoulos & Lai,
2005a). In topology studies the central domain cluster (2246–2534)
was mapped to the N-terminus region, which was not consistent with
the sitemapped for FKBP12 binding to RyR1 (Wagenknecht et al., 1997).
Others have proposed a different binding site using recombinant
constructs of the RyR sequence — one in the N-terminus (305–1937)
(Masumiya et al., 2003) and another at the C-terminus potentially
involving VPLV (4594–4597 hRyR2) (Zissimopoulos & Lai, 2005a). Thus
to date the region of RyR1/2 binding to FKBP12/12.6 has deﬁed precise
deﬁnition.
Some studies have shown that FKBP12/12.6 act to stabilise RyR1/2
and inhibit channel activity reducing Po in bilayer studies (Brillantes
et al.,1994; Chen et al.,1994;Maet al.,1995). Theseeffectswere reversed
by FK506, which binds to FKBP12/12.6 at its RyR binding site and
inhibits interaction (Chelu et al., 2004). The resultwas to increase Po and
in some experiments sub-conductance states were seen leading to the
conclusion that FKBP12/12.6 binding might stabilise RyR inter subunit
interactions (Brillantes et al., 1994; Ahern et al., 1997).
A secondaction of FKBP12/12.6maybe tomodulate, functionally but
not structurally, coupled gating (Marx et al.,1998;Marx et al., 2001a). In
situ RyRs are organised in 2D arrays (Franzini-Armstrong et al., 2005)
and in this 2D arrangement the binding domain for FKBP12 is distinct
from the RyR–RyR interacting domains 6 (Wagenknecht et al.,1997; Yin
et al., 2005a) and divergent region 2 (Liu et al., 2004). A study of RyR1
oligomeric interaction using photon correlation spectroscopy showed
no difference in association with or without added FKBP12 (Hu et al.,
2005).
FKBP12.6 overexpression resulted in a decreased number of
spontaneous Ca2+ sparks which were of decreased amplitude, width
and duration in both mouse (Gomez et al., 2004) and rabbit cardio-
myocytes (Loughrey et al., 2004). This was interpreted as an effect on
decreasing diastolic Ca2+ leak particularly as this was accompanied by
an increase in the SR Ca2+ store content (Gomez et al., 2004).
However, the Ca2+ transient amplitude was increased, which ac-
counted for the observed increases in contractility and thus the
equivalent of improved systolic functionwas seen (Prestle et al., 2001;
Gomez et al., 2004). A similar increase in store Ca2+ and an increased
Ca2+ transient were observed in rabbit cardiomyocytes (Loughrey
et al., 2004). It was concluded that the changed dynamics of Ca2+
release may result from improved coupled gating and early termina-
tion of the spark by FKBP12.6 (Gomez et al., 2004; Loughrey et al.,
2004). Generally the effects of FK506 on cardiomyocytes were the
reverse of FKBP12.6 overexpression. Differences were observed,
however, between rat and rabbit cardiomyocytes. The latter showed
a decrease in SR store Ca2+ which was attributed to the greater
reliance on NCXextrusion of released Ca2+ in rabbit decreasing dyadic
Ca2+ concentration, despite increased Ca2+ diastolic leak caused by
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can also bind to RyR2 (Jeyakumar et al., 1998) but co-expression with
RyR2 in CHO cells did not functionally modulate the channel, whereas
FKBP12.6 expression rescued these cells from loss of viability and
abnormalities of Ca2+ signalling (George et al., 2003). FKBP12 over
expression in rabbit ventricular myocytes, however, modulated ECC in
a manner which suggested that it reduced RyR2 sensitivity to Ca2+
(Seidler et al., 2007) but was different from overexpression of
FKBP12.6 (Loughrey et al., 2004).
Two models of FKBP12.6 knockout mice have been produced in
different strains, which show different characteristics. In one the
males, but not females, developed hypertrophy and the mice showed
evidence of perturbed Ca2+ signalling ‘at rest’ as CICR gain was
increased manifest as an increase in amplitude and duration of
spontaneous Ca2+ sparks (Xin et al., 2002). In the secondmodel there
was no evidence of hypertrophy and at rest Ca2+ signalling was
similar to that of WT mice however, when the hearts were paced or
given an isoprenaline injection arrythmogenic beats were observed
(Lehnart et al., 2006), in contrast to the other model, which showed
no arrhythmic tendencies when challenged with caffeine plus
epinephrine (Xiao et al., 2007b). It has been suggested that the
surprisingly moderate effects of FKBP12.6 ablation on ECC (and RyR2
in particular) might be attributable to surrogate regulation by FKBP12
in these animals (Seidler et al., 2007).
The importance of regulation by FKBP12/12.6 is therefore
contentious and particularly relevant to the proposed mechanisms
of RyR2 dysfunction in HF and CPVT (see Sections 4.1.2.2 and 4.2.3.2).
3. Ryanodine receptor molecular structure
RyR is a homotetramer with a central Ca2+ pore and each subunit
has a molecular mass of ∼560 kDa making RyR the largest known
Ca2+ channel protein with a molecular mass of ∼2200 kDa (Lai et al.,
1988). The homotetramer is extremely stable and the puriﬁed
protein, because of its enormous size, is amenable to cryo-electron
microscopy and image analysis to produce electron density maps of
the molecule (Samso & Wagenknecht, 1998; Serysheva, 2004) at
14 A (Serysheva et al., 2005) and ∼30 A (Radermacher et al., 1994;
Sharma et al., 1998). These topology models have revealed a
tetragonal structure with a large cytoplasmic region and a
transmembrane ‘stalk’ — see Fig. 4. C terminus constructs of RyR2
expressed in CHO cells (3550–4976 (Bhat et al., 1997), 3722–4967
and 4485–4967 (George et al., 2004)) all formed tetrameric Ca2+
channels, albeit poorly regulated. The extreme C terminus 100
amino acids of RyR2 were able to self tetramerise (Stewart et al.,
2003) and the mutation of key charged residues within this region
of RyR1 suggested that electrostatic interactions may contribute to
tetramerisation (Lee & Allen, 2007). Deletion of the ﬁnal 15 amino
acids from a full length construct of RyR1 impaired tetramer
formation (Gao et al., 1997). Sequence analysis of the RyR protein
shows that the C terminus sequence (the last 20% of the full length)
contains up to 12 hydrophobic helical regions, which could be the
transmembrane domains (Takeshima et al., 1989; Nakai et al., 1990;
Otsu et al., 1990; Zorzato et al., 1990; Hakamata et al., 1992; Tunwell
et al., 1996). Models suggest 4 (Takeshima et al., 1989), 6 (Tunwell et
al., 1996), 12 (Zorzato et al., 1990) or 6–8 transmembrane regions
per monomer with one potential transmembrane stretch forming a
pore loop from the luminal side (Du et al., 2002). The latter bears
sequence homology to the K+ channel pore loop and mutations in
this loop of RyR2 had severe consequences on conductance and
ryanodine binding (Zhao et al., 1999). Comparative modelling of the
extreme RyR2 C-terminus loops, with (KcsA) K+ channel crystal
structure (Doyle et al., 1998), revealed equivalent arrangement and
structure (Welch et al., 2004). A high resolution cryo-EM study at
∼10 A (of the closed RyR1 molecule) revealed a transmembrane
substructure similar to that of the K+ channel (KscA) for the innerhelix of each monomer but a poor ﬁt for the outer helices (Samso et
al., 2005). A second high resolution cryo EM study of the closed
RyR1 molecule (Ludtke et al., 2005) compared the projected helical
densities with K+ channel structures and found a closest structural
ﬁt to the MthK channel (Jiang et al., 2002c). The precise number of
transmembrane loops is unknown but such knowledge may be very
important to understanding the internal RyR molecular interactions
which gate the channel between its open and closed conﬁgurations.
The topology models show that the RyR1/RyR2 molecule
undergoes domain rearrangement(s) during the open to closed
conductive transition (Orlova et al., 1996; Serysheva et al., 1999) and
RyR2 has a different conformation when bound to FKBP12.6
(Sharma et al., 2006). There is evidence from mapping that the N
terminus (Liu et al., 2001), the N-terminus CPVT mutational cluster
of RyR2 (amino acids 414–466, GFP insertion at S437 (Wang et al.,
2007)) and central domain region containing CPVT point mutations
(GFP insertion at 2367) (Liu et al., 2005) are located at the corners of
the molecule in the clamp regions (see Fig. 4). The many domains
which map to this corner of the molecule, when compared to the
sequence of RyR, demonstrate how the tertiary structure of the
protein may bring together quite distant regions of the protein
sequence by convoluted folding. If, as shown by the difference in the
closed and open states, the N-terminus is a domain that is
particularly susceptible to conformational change it maybe vulner-
able to molecular rearrangements that actually originate elsewhere
in the molecule such as an allosteric shift caused by the binding of a
modulatory protein or the insertion of a tag such as GFP.
3.1. Conformational change and ryanodine receptor domain interaction
One of the unknowns in RyR channel gating is how the four
subunits of RyR work together and the domain interactions
discussed below may be intrasubunit or intersubunit in origin.
The RyR molecule is extremely stable in that puriﬁed protein
maintains its homotetrameric structure in the presence of mild
detergents (Lai et al., 1989). The C-terminus domain has been
identiﬁed as a necessary requirement for tetramerisation (Gao
et al., 1997; Stewart et al., 2003). The importance of interdomain
interactions were illustrated by crosslinking studies (Wu et al.,
1997). The involvement of the N-terminal region to domain
interaction was highlighted by the action of a monoclonal antibody
to the G341 region of RyR1, which increased the Ca2+ sensitivity
and ryanodine binding of SR vesicles and inhibited interaction in
overlay assays with domains 799–1172 and 3010–3225 (Zorzato
et al., 1996) the latter having been identiﬁed as a calmodulin
binding domain (Menegazzi et al., 1994). Peptides to the N-
terminus domain were shown to alter ryanodine binding and SR
Ca2+ release in cardiac and skeletal muscle microsomes. It was
concluded that the peptide could insinuate between the interacting
domains and disrupt interaction by binding to the partner domain
(El-Hayek et al., 1999). The synthetic peptide DP4 (2442–2477 of
RyR1) was able to disrupt a proposed N-terminus/central zipper
domain interaction, Fig. 4, (Yamamoto et al., 2000) and was able to
increase Ca2+ spark frequency in permeabilised frog skeletal
muscle ﬁbres (Shtifman et al., 2002). A similar peptide was
produced for RyR2 studies DPc10 (G2460–P2495) and increased the
sensitivity of RyR2 to activating Ca2+ and increased ryanodine binding
(Yamamoto & Ikemoto, 2002).
Another interdomain interaction is proposed between the two
C-terminus regions 3534–4610 and 4497–4959 (George et al.,
2004). The latter correspond to the sequence postulated to contain
the transmembrane segments according to the six transmembrane
model (Williams et al., 2001; Du et al., 2002), which surround the
channel pore. The 3722–4610 sequence consists of regions of
hydrophobic domains. When it was expressed as an independent
tagged peptide it interacted with and regulated the C-terminal pore
Fig. 4. RyR2 structure and the relationship to important domains associated with function, regulatory proteins and CPVT point mutations. The upper diagram is a schematic
illustration of the RyR2 polypeptide sequence with the proposed locations of modulatory protein binding sites for FKBP12.6 (dotted grey oval with arrows) (Marx et al., 2000;
Masumiya et al., 2003; Zissimopoulos & Lai, 2005b) and for CM (grey oval above the transmembrane domain). CPVT mutation clusters are illustrated within the RyR2 polypeptide as
dotted lines, with amino acid numbers in italics indicating their boundaries (residues 1–466, 2246–2534, 3778–4201, 4497–4959). Divergent regions identiﬁed within the RyR2
sequence numbering given (DR 1, DR 2 or DR 3) are shown by an asterisk (Liu et al., 2002; Zhang et al., 2003a; Liu et al., 2004). The position of CPVTmutation S437 (Wang et al., 2007)
and S2367 (Liu et al., 2005), which have beenmapped to the corner region of RyR2 (see below) by insertion of GFP into the RyR2 sequence are shown. Two PKA phosphorylation sites,
P2808 (Meng et al., 2007) and P2030 (Jones et al., 2007) are bothmarked and have also beenmapped. The lower ﬁgure is a topologymodel of RyR1 structure, viewed from the cytosol
(modiﬁed from Serysheva et al., 1999; Fig. 3, with permission) depicting the open channel conformation (right panel; 100 µM Ca2+ plus AMP–PCP) compared to the closed channel
(left panel; EGTA). Noted by an asterisk is the signiﬁcant change in each corner of the structure apparent when comparing the closed versus open RyR conformation. Indicated by
arrows on the closed conformation, are the proposed locations of some of the domains mentioned above; PKA S2030 phosphorylation site (Jones et al., 2007), PKA S2809
phosphorylation site (Meng et al., 2007) the N-terminus (Liu et al., 2001), S437-GFP (Wang et al., 2007), DR1 (Liu et al., 2002), DR2 (Liu et al., 2004), DR3 (Zhang et al., 2003a),
S2367-GFP (Liu et al., 2005) and the proposed binding locations of FKBP12 and calmodulin (Wagenknecht et al., 1997). These sites are illustrated with greater precision in the original
papers, and these also show their locations in other viewing angles, but their clustered distribution illustrated here suggests that the RyR corner region (encircled with dotted line)
may be important in regulation of the conformational changes that mediate channel gating. Note also the apparent close proximity of several distant regions of the RyR linear
sequence suggesting signiﬁcant contribution of protein folding to the overall RyR channel structure.
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3534–4610 sequence was termed the I-domain and is rich in
residues, domains and motifs implicated in channel regulation
(George et al., 2006). Many of these have been characterised in
RyR1 or RyR3 but are conserved and have homologous regions in
RyR2. The Ca2+ sensor residue was identiﬁed in RyR3 but the
homologous residue in RyR2 is E3988 — this charged residue was
mutated to alanine resulting in a 10,000-fold decrease in Ca2+
sensitivity (Chen et al., 1998). 4-chloro-m-cresol, which like
caffeine is used as a pharmacological activator of RyR channels,
required residues Q4020 and K4021 to activate RyR1 (Fessenden
et al., 2006). The 3778–4201 domain is also proposed (in RyR1) to
contain a CaM-like binding domain 3534–4610, which may interact
with the CaM binding site in the 3614–3643 region (Xiong et al.,
2006). These domain interactions are proposed to maintain the
channel in its closed state but undergo a conformational change as
part of the molecular rearrangement of the RyR as it gates from the
closed to open conductive state.
The tetragonal symmetry of the RyR provides four identical
regulatory sites for every RyR modiﬁcation or interaction. It is
unknown whether they require saturation (i.e all sites to be
occupied) or whether there is any co-operativity once one subunit
is modiﬁed. In this respect it has been calculated that thestoichiometry for RyR2 and FKBP12.6 is N1:3 (Timerman et al.,
1996). It has been proposed that RyR2 from sheep heart is normally
75% phosphorylated (Carter et al., 2006). It is also not known
whether the postulated interdomain contacts e.g. between zipper
domains, is internal to one subunit or involves inter-subunit
interaction. Even with one interaction and four sites it is calculated
that there are 54 combinations in which a single modulator can
interact with a tetrameric molecule (Bray & Duke, 2004). With so
many modulators, including interacting with itself in an array (Yin
et al., 2005a), the potential heterogeneity of modulation, which can
be experienced by a single RyR molecule reaches theoretically
mind-numbing proportions. Yet there is no evidence that this
usually causes the RyR any functional difﬁculty and how the RyR
actually overcomes this theoretical problem, and whether it impacts
on function in pathological circumstances, is unknown and
experimentally difﬁcult to address.
4. Ryanodine receptor type-2 and
the pathophysiology of fatal arrhythmia
The dysfunction of RyR2 resulting in Ca2+ diastolic leak causing
DADs is a feature of fatal arrhythmia in HF and CPVT. Patients with the
latter condition carry point mutations in the RyR2 gene. In CPVT
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adrenergic drive (Priori et al., 2002). In HF persistent circulating levels
of catecholamines are associated with disease progression (Lohse
et al., 2003; Molenaar & Parsonage, 2005). Thus both conditions are
causally linked to mechanisms involving phosphorylation. The role of
RyR2 in the pathophysiology of HF and CPVT will be discussed in the
context of its role in ECC, and the mechanisms underlying dysfunction
and how these might be changed by phosphorylation, RyR2 interac-
tion with regulatory proteins, Ca2+ homeostasis or abnormal intra
RyR2 domain interactions.
4.1. Heart failure
In Britain 750,000 people are living with HF (www.bhf.org.uk) and
statistics suggest that 50% will eventually die from SCD associated with
an arrhythmic episode, usually a ventricular tachycardia (VT) leading to
ventricular ﬁbrillation (Tomaselli & Zipes, 2004). HF is a disease of
complex aetiology, originating from diverse causes with different rates
and phenotypic pathways of progression (Hasenfuss & Pieske, 2002;
Sipido & Eisner, 2005; Swynghedauw, 2006) raising the question as to
whether these are all likely to converge to a common mechanism
causing VT and SCD (Pogwizd & Bers, 2004; Tomaselli & Zipes, 2004).
There are a number of deﬁning features of HF. The human
myocardium shows depressed contractility and a negative force
frequency relationship — essentially as the heart rate increases the
failing heart becomesmore distressed (Hermann et al., 1999; Hasenfuss
et al., 2002). There is compelling evidence at the myocyte level that the
progression to HF eventually results in defects in ECC, most speciﬁcally
changes in Ca2+ homeostasis and a depressed level of the SR Ca2+ store
(Hermannet al.,1999; Belevychet al., 2007) and the resultant decreased
release Ca2+ from the SR at each beat becomes insufﬁcient to fully
activate themyoﬁlaments. This scenario is observed inbothexperiments
from animal models (Eising et al., 1994; Hobai & O'Rourke, 2001; Jiang
et al., 2002b; Belevych et al., 2007) and on tissue from human
myocardium obtained from transplant patients (Gwathmey et al.,
1987; Hasenfuss et al., 1994; Beuckelmann et al., 1995; Hermann et al.,
1999; Pogwizd et al., 2001; Jiang et al., 2002b; Piacentino et al., 2003).
Reduced SR Ca2+ content can arise by a decrease in SERCA expression or
degree of activation by PLB or through increased diastolic leak via RyR2
(Bers et al., 2003; Belevych et al., 2007).
The changes characteristic of HF, that are outlines brieﬂy above,
can result in arrhythmia but the causative molecular mechanisms are
controversial. Global changes in ECC can, because of RyR2's pivotal
position, cause dysfunctional changes in RyR2 activity that are difﬁcult
to disentangle from innate alterations in the RyR2 protein. The latter
includes direct modiﬁcations such as phosphorylation by PKA and/or
CaMKII and oxidation. There are also potential changes in the stoi-
chiometry with regulatory proteins to consider and loss of FKBP12.6
has been the object of speciﬁc focus. Variations in the dynamics and/
or concentration of activating or luminal Ca2+ may be caused by
functional changes in other Ca2+ pumps, ion channels or exchangers
and inﬂuence RyR2 channel gating.
In addition to RyR2-centred mechanisms, there are other causes of
arrhythmia in HF and these are comprehensively reviewed elsewhere
(Pogwizd & Bers, 2004; Scoote & Williams, 2004; Tomaselli & Zipes,
2004).
4.1.1. Changes in protein expression
HF is mostly a progressive disease, which involves remodelling of
the whole organ and of the cardiomyocyte andmany of the changes in
myocyte function may result from altered patterns of gene expression
(Swynghedauw, 2006). Both PKA (Pare et al., 2005; Bauman et al.,
2007) and CaMKII (Maier & Bers, 2002) phosphorylate components of
gene transcription pathways and thus have dual roles in ECC and
excitation–transcription coupling. The latter involves regulation of
gene expression in response to raised Ca2+ (Bare et al., 2005; Wu &Bers, 2006). In this context LCC activity is linked to regulation of K+
channel expression (Richard et al., 2006). Ca2+/CM provides a link to
calcineurin via the NFAT transcription factor (Jones et al., 2003),
which is for example activated during the progression of pathological
hypertrophy (Wilkins et al., 2004).
Changes in expression of most of the proteins associated with the
ECC cycle have been reported inHF in both animalmodels and human
heart. Generally expression of SERCA is depressed (Williams et al.,
1994; Kiss et al., 1995; Zarain-Herzberg et al., 1996) and the extent
may mirror the severity of the symptoms seen in human failing and
non-failing hearts (Hasenfuss et al., 1994) and be time dependent
(Sallinen et al., 2007). Conversely in human heart NCX is increased
(Hasenfuss et al., 1994; Reinecke et al., 1996; O'Rourke et al., 1999;
Schwinger et al., 1999b; Pogwizd, 2000; Litwin & Zhang, 2002). This
combination of increased NCX and decreased SERCA expression
favours increased cellular extrusion and decreased store Ca2+,
limiting cytosolic Ca2+ available for contractile protein deinhibition.
Phosphatase inhibitor protein (P-1), which inhibits PP1 activity, is
decreased in human HF (El-Armouche et al., 2004) and PP1 levels
were increased in a rat model of HF (Huang et al., 1999). Thus
phosphatase activity would be increased and PLB in particular would
be dephosphorylated limiting SERCA activity and uptake into Ca2+
stores. RyR2 expression has been reported to be decreased in HF by
25% in rabbit (Ai et al., 2005) or ∼30% in canine (Song et al., 2005)
models of aortic insufﬁciency, 48% in a canine model of chronic HF by
pacing (Kubalova et al., 2005) and 35% in human heart (Go et al.,
1995).
RyR2 is regulated by a number of accessory proteinsmany of which
are reported to co-immunoprecipitate as part of a macromolecular
complex (Bers, 2004), which includes a number of proteins —
phosphodiesterase 4D (PDE4D3) (Lehnart et al., 2005b), FKBP12.6
(Collins, 1991; Jayaraman et al., 1992), PKA, PP1 and PP2A (Marx et al.,
2001b) and CaMKII (Currie & Smith, 1999; Wu et al., 2001; Zhang
et al., 2003b;Wehrens et al., 2004b), Fig. 3. FKBP12.6, PP2A and PPI are
reported to be lost from the complex in HF in a paced dog model
(Marx et al., 2000; Yano et al., 2000) and in a rabbit model of aortic
constriction (Ai et al., 2005) and in human HF (Marx et al., 2000).
Decrease in expression levels or binding afﬁnity for RyR2 may both be
contributory factors and the evidence for the individual changes are
discussed in the appropriate sections below.
4.1.2. Molecular mechanisms of ryanodine receptor type-2 dysfunction
The cause of RyR2 dysfunction is highly controversial and may
involve a number of potential mechanisms. The hyperphosphorylation
hypothesis (Marx et al., 2000) proposes that the loss of phosphatases
is responsible for the hyperphosphorylation of RyR2 and that this
caused the loss of the modulator protein FKBP12.6 from the RyR2
complex (Marx et al., 2000; Yano et al., 2000). This would cause
instabilities in RyR2 channel gating leading to increased diastolic leak
from RyR2 setting up the conditions to generate DADs. This
hypothesis, however, it is not without its detractors but it has
provided both the impetus and focus for a lively debate about the
mechanisms underlying RyR dysfunction. Another hypothesis con-
cerns interacting domains of the RyR2 molecule that ‘unzip’ as part of
the molecular rearrangement regulating channel gating between the
open and closed conductive states — interactions which may be
susceptible to oxidation (Oda et al., 2005; Yano et al., 2005). Increased
sensitivity of RyR2 to luminal Ca2+ has also been reported in HF
(Kubalova et al., 2005).
4.1.2.1. Ryanodine receptor type-2 hyperphosphorylation. The devel-
opment of HF is associated with increased levels of circulating
catecholamines and persistant β-adrenergic stimulation which, as a
protective compensatory mechanism, leads to decreased receptor
expression and cAMP production by adenyl cyclase and hence decreased
PKA activation (Bristowet al.,1982). In this regard, the deleterious effects
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expression of the active subunit of PKA in transgenic mice, which
resulted in cardiomyopathy, decreased contractility, arrhythmia and
susceptibility to SCD (Antos et al., 2001). Conversely, symptoms of HF,
including restored SR function and reducedCa2+ leak, canbe ameliorated
by pretreating paced dogs with β-blockers (Reiken et al., 2001; Doi et al.,
2002) or the AT1 receptor antagonist — valsartan, which inhibits
noradrenaline release from the synaptic pool (Tokuhisa et al., 2006).
Many proteins in ECC are co-ordinately upregulated by PKA
phosphorylation during the normal ‘ﬂight or ﬁght’ response resulting
in faster Ca2+ cycling. This upregulation is ultimately balanced by
dephosphorylation by phosphatases (Bers, 2002), Fig. 3. In HF PP1
protein levels are reported to be increased (Neumann et al., 1997;
Huang et al., 1999) and expression of its inhibitor PI-1 decreased (El-
Armouche et al., 2004), which should predict hypophosphorylation, as
is reported for PLB (Huang et al., 1999; Dash et al., 2001) with residues
T16 and T17 showing reduced phosphorylation (Schwinger et al.,
1998; Huang et al., 1999). This may be one of the causative factors for
the reduced SR Ca2+ store in HF as SERCA activity is repressed by
dephosphorylated PLB (MacLennan & Kranias, 2003). Animal models
of phosphatase overexpression can cause HF by producing hypopho-
sphorylation of key ECC proteins (Carr et al., 2002; Gergs et al., 2004;
Kirchhefer et al., 2005). Conversely overexpression of PI-1/2, the
phosphatase inhibitory protein can rescue HF and up-regulate SERCA
activity (via PLB) and raise SR store Ca2+ (Pathak et al., 2005; Yamada
et al., 2006). Perversely, RyR2 is reportedly hyperphosphorylated in a
number of studies (Marx et al., 2000b; Yano et al., 2000; Ai et al.,
2005; Song et al., 2005) but unchanged in others (Jiang et al., 2002b;
Xiao et al., 2005). Thus disruption of the ﬁdelity of ECC in HF can be
viewed as the loss of co-ordinated regulation by phosphorylation
(Sipido & Eisner, 2005).
4.1.2.1.1. Why is ryanodine receptor type-2 hyperphosphorylated?
The crux of the RyR hyperphosphorylation hypothesis is its micro-
domain complex (Bers, 2004), fromwhich key proteins can be lost in
isolation from the general cellular milieu. These include the
phosphatases PP1 and PP2A in the paced dog model (Marx et al.,
2000; Yano et al., 2000), human failing heart (Marx et al., 2000) and in
a rabbit model of aortic constriction (Ai et al., 2005). In addition,
PDE4D3 (which metabolises cAMP) is reduced in human HF and
PDE4D3-deﬁcient mice have been shown to develop cardiomyopathy
and exercise-induced arrhythmias (Lehnart et al., 2005b). It is
proposed that, in the vicinity of the RyR2 complex/microdomain,
cAMP levels would remain high because PDE4D3 is lost, thus
activating PKA phosphorylation of RyR2. Phosphorylation would
persist because the phosphatases PP1 and PP2A have also been lost
from the complex (Marks, 2003).
4.1.2.1.2. What is hyperphosphorylation? There are several RyR2
phosphorylation sites and there is no consensus view on which are
fully phosphorylated in HF or those that are the most important. The
S2809 residue has been shown experimentally to be hyperpho-
sphorylated in HF in a paced dog model and in myocardium from
human transplant (Marx et al., 2000). The importance of the S2809
residue was further emphasised using a knock-in mouse model with
an S2809A mutation site — a residue which could not be PKA
phosphorylated, and these mice did not develop such severe
symptoms of HF, following myocardial infarction, as WT mice
(Wehrens et al., 2006). These same S2809A mice were also protected
when given an antagonist to inhibit PDE4D3 (hence raise cAMP) and
challenged with isoprenaline, a regime, which caused hyperpho-
sphorylated RyR2 and fatal arrhythmia in WT (Lehnart et al., 2005b).
In contrast, using a paced dog model it has been shown that S2809
phosphorylation was unchanged in HF (Jiang et al., 2002b; Xiao et al.,
2005) and a different residue — S2030, showed PKA-dependent
phosphorylation (Xiao et al., 2005).
A number of studies have explored the role of CaMKII in
hypertrophy and HF in both human (Hoch et al., 1999) and animalstudies (Currie & Smith, 1999; Hagemann et al., 2001; Ai et al., 2005).
CaMKII, like PKA, is upregulated in hypertrophy and HF and shown to
phosphorylate LCC, PLB on T17 and RyR2 (Zhang & Brown, 2004).
Three-fold over expression of CaMKII in a transgenic mouse model
resulted in HF at three months and the isolated cardiomyocytes
showed a 50% reduction in SR store Ca2+, with reduced SERCA and
increased NCX expression together with an increase in spontaneous
Ca2+ sparks suggesting diastolic leak from RyR2 (Maier et al., 2003).
Another study, in a rabbit model of aortic constriction, measured
increases of 63% in total CaMKII protein and 43% in autopho-
sphorylated CaMKII with an increase in phosphorylation of PLB at
T17 (and decreased phosphorylation of S16) and both S2809 and
S2815 of RyR2 were phosphorylated (Ai et al., 2005). In the same
study, by using either a PKA (H-89) or CaMKII (KN-93) inhibitor, it
was shown that KN-93 could decrease diastolic leak from SR and
increase the Ca2+ transient whereas inhibiting PKA activity had no
effect. This suggested that the major protagonist of RyR hyperpho-
sphorylation in HF was CaMKII and not PKA (Ai et al., 2005). In
support, it has been shown that CaMKII inhibition by inhibitory
peptides suppressed transient inward currents, which originated from
NCX reversal and which were associated with DADs (Wu et al., 1999).
4.1.2.1.3. How does hyperphosphorylation modulate ryanodine
receptor type-2? One of the problems with answering this question
is the lack of consensus in experimental results and indeed any real
mechanistic understanding of how phosphorylation normally alters
RyR channel gating. This has been outlined in Section 2.4. Phosphor-
ylation by CaMKII may regulate RyR2 differently from PKA as, apart
from S2809, they have different phosphorylation sites (Rodriguez et
al., 2003). It is proposed that hyperphosphorylation of RyR2
perpetrates the loss of the modulatory protein FKBP12.6 (Marx et
al., 2000) and it is this which results in RyR2 dysfunction.
4.1.2.2. FKBP12.6 loss and ryanodine receptor type-2 dysfunction.
FKBP12.6 is a potent regulator of RyR2 function and the loss (by
addition of FK506) of FKBP12/12.6 from normal channels results in
RyR dysfunction including increased Po and subconductance states in
single channel studies (Brillantes et al., 1994; Chen et al., 1994; Ma
et al., 1995) and increase in Ca2+ spark frequency in cardiomyocytes
(Gomez et al., 2004; Loughrey et al., 2004). The relationship between
FKBP12.6 loss and phosphorylation causing arrhythmia has been
explored in FKBP12.6 -/- and +/- cross bred mice (Xin et al., 2002;
Lehnart et al., 2006). Disconcertingly the models showed different
characteristics. In one, no arrhythmia was seen at rest and isoprena-
line injectionwas necessary to produce arrythmogenic beats (Lehnart
et al., 2006). In the other CICR gainwas increased at rest—manifest as
an increase in the amplitude and duration of spontaneous Ca2+ sparks
(Xin et al., 2002). The reason for this difference was not clear, but both
models illustrate that there is compensation for the loss of FKBP12.6
which is not lethal.
It has been proposed that in HF hyperphosphoryation by PKA of
S2809 speciﬁcally causes the loss of the RyR2 modulatory protein
FKBP12.6 (Yano et al., 2000) whereas CaMKII (Wehrens et al., 2004b)
or PKC did not cause a similar dissociation (Marx et al., 2000;Wehrens
et al., 2004b), although CaMKII is reported to phosphorylate S2809
(Witcher et al., 1991; Marx et al., 2000; Rodriguez et al., 2003). A
decrease in the ratio of [3H]FK506 to [3H]ryanodine was measured in
microsomal fractions prepared from a 4 week paced dog model of HF
(Yano et al., 2000). A ﬂuorescent probe technique, which measured
conformational change in RyR2 on the addition of FK506, showed
little change in ﬂuorescence in the paced dogs implying that the
FKBP12.6 had already been lost (Yano et al., 2000). Using the same
paced dog model a second group also showed a loss of FKBP12.6
together with decreased levels of PP1 and PP2A in a RyR2 complex
that was solubilised from microsomes (Marx et al., 2000). The loss of
FKBP12.6 was attributed to the hyperphosphorylated state of RyR2
since in one study, phosphorylation of RyR2 from control dogs was
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furthermore, these effects could be reversed by ﬁtting the paced dogs
with a left ventricular assist device (LVAD) which aided recovery of
contractile function (Marx et al., 2000).
One study showed a decrease of 66% in FKBP12.6 associated with
SR (paced dog) (Yano et al., 2000) but another has shown no change
in the paced dog model or human HF (Jiang et al., 2002b). Other
studies, measuring the FKBP12.6 that can be immunoprecipitated
with the solubilised RyR2 complex, demonstrated a decrease in the
FKBP12.6/RyR2 ratio of 50% (paced dog) or 65% (human HF) (Marx
et al., 2000) or 38% (rabbit aortic insufﬁciency) (Ai et al., 2005).
4.1.2.2.1. What might cause FKBP12.6 loss? For RyR2 to lose
FKBP12.6 from its binding site the binding afﬁnity must either change
or the concentration of FKBP12.6 must fall and there is evidence for
both.
It has been proposed that the addition of the negatively charged
phosphate onto RyR2 S2809 by PKA results in a charge repulsion
preventing FKBP12.6 binding (Wehrens et al., 2006). Removing the
negatively charged D37 residue of FKBP 12.6 — a part of its binding
domain to RyR2 by substitutionwith V or S increased FKBP12.6 binding
to PKA phosphorylated SR vesicles or the S2808D RyR2 mutant
expressed in HEK293 cells (Wehrens et al., 2003). Single channel
studies showed that binding the D37V mutant could decrease the Po of
S2808D RyR2 and ‘stabilise’ channel activity (Wehrens et al., 2006).
However, it is unlikely that there is a direct interaction between the
proposed phosphorylation site(s) (Jones et al., 2007; Meng et al., 2007)
and FKBP12.6 (Wagenknecht et al., 1997) as these map on the topology
models to different regions of the RyR structure— Fig. 4. Thiswould give
credence to the view that phosphorylation invokes an internal mole-
cular rearrangement of RyRwhich alters the afﬁnity for FKBP12.6 (Jones
et al., 2006). Other studies have also examined the phosphorylation
status of S2808 and FKBP12.6 binding using HEK293 cells and both
concluded that there was no relationship. Expression of mutant RyR2
S2808D or S2808A and its RyR1 homologue S2843D or S2843A, showed
no change in the binding to FKBP12.6/12, of the mutated RyR channels
and no differences the Ca2+ dependence of single channel activity,
although the latter experiment did not include the effect of FKBP12.6/12
addition (Stange et al., 2003). Similar experiments, and in addition, pull-
downassays frommicrosomesof canine cardiacmusclewith eitherGST-
FKBP12.6 or antibody to RyR2, showed an unchanged association of
FKBP12.6 to RyR2 whether or not the latter was phosphorylated (Xiao
et al., 2004).
Using Biacore technology, to measure the equilibrium binding
kinetics of interaction between RyR1 and FKBP12 it was shown that
afﬁnity of solubilised RyR1 for FKBP12 is lower for the open channel
than the closed (Jones et al., 2005) and this is also true for RyR2
(unpublished observations). The effect of PKA phosphorylationwas to
shift the afﬁnity of the closed channel to the lower afﬁnity of the open
channel, nonetheless, the afﬁnity for the open state was still high
(Jones et al., 2005). It was concluded that the shift in afﬁnity was part
of the normal ‘ﬂight or ﬁght’ response mechanism. The equilibrium
binding data was interpreted as demonstrating a change in conforma-
tion of RyR when phosphorylated — possibly a molecular movement
to a state which would favour the open/closed transition (Jones et al.,
2006). This is consistent with conclusions from single channel studies
(Valdivia et al., 1995) and in myocytes from PLB-DMmice (Ginsburg &
Bers, 2004), that RyR2 must open and close more rapidly to facilitate
upregulation of ECC by phosphorylation. The domain zipping
hypothesis also predicts a molecular movement within the RyR2
molecule (Oda et al., 2005), see Section 4.1.3. A decrease in afﬁnity of
FKBP12.6 to the open or phosphorylated channel could translate into a
loss of FKBP12.6 during the isolation of either the RyR2 complex or SR
vesicles, since the rate of dissociationwould be greater once RyR2 was
no longer exposed to free FKBP12.6, within its microdomain
environment.FKBP12.6 distribution has been difﬁcult to determine at the
cellular level as cardiac muscle contains high levels of the FKBP12
isoform as well as the cardiospeciﬁc FKBP12.6 (Timerman et al., 1996)
and no distinguishing antibodies have been available. Measuring
mRNA FKBP12.6 and FKBP12 levels showed 49% and 20% decreases
respectively in HF (rabbit banded aorta) which corresponded to a 38%
decrease in the FKBP12.6/RyR2 ratio (Ai et al., 2005).
There are many unresolved issues surrounding the relationship
between FKBP12.6 and RyR2. In particular, it is not at all clear in those
studies in which FKBP12.6 is lost in HF, whether this is due to reduced
expression or decrease in afﬁnity.
4.1.3. Oxidation and domain unzipping
Evidence for the contribution of oxidative stress to the develop-
ment of HF is considered by some to be inconclusive (Mak & Newton,
2001; Giordano, 2005). However, others propose that there is good
evidence that oxidative stress is involved in many of the pathological
remodelling processes that ultimately lead to HF (Sawyer et al., 2002).
Several of the protein components of ECC including RyR are modiﬁed
by oxidation (Choudhary & Dudley, 2002; Pessah et al., 2002). RyR
contains a number of active cysteine residues which are susceptible to
modulation by the redox state of the channel (Xu et al.,1998; Sun et al.,
2001). Oxidation of RyR increases ryanodine binding (Xia et al., 2000)
and increases Po in bilayer studies (Marengo et al., 1998). For reviews
see (Zima & Blatter, 2006; Zissimopoulos & Lai, 2006). Using a 4 week
paced dog model the synthetic antioxidant edaravone was able to
improve the haemodynamic properties and contractile function of
myocytes, improve SR function by restoring SERCA protein levels and
reverse hyperphosphorylation of RyR restoring FKBP12.6 binding
(Yano et al., 2005). In vitro studies, using pull down assays has shown
that oxidation of RyR2 can reduce binding to recombinant FKBP12.6
(Zissimopoulos & Lai, 2006). Exposure to reactive oxygen species,
produced during the development of HF, could cause domain
unzipping and edaravone could prevent this (Choudhary & Dudley,
2002).
The DPc10 peptide was used to target a ﬂuorescent indicator into
the zipper domain where it was cross-linked to RyR2 protein
(Yamamoto & Ikemoto, 2002). A ﬂuorescence quencher attached to
BSA could only access the domain when unzipped and was used to
measure state of this domain in SR from both normal and HF (paced
dog). It was shown that this domain could be unzipped in normal SR
by the oxidant SIN-1 (Yano et al., 2005) but was already unzipped in
HF (Oda et al., 2005). In SR from control dogs, application of cAMP to
phosphorylate RyR could also unzip the domain and this was
associated with loss of FKBP12.6, implying that phosphorylation
could cause domain unzipping but unzipping by DPc10 alone did not
dissociate FKBP12.6 (Oda et al., 2005).
4.1.4. Ryanodine receptor type-2 sensitivity to luminal Ca2+
Some studies have reported increased numbers of Ca2+ sparks in
myocytes isolated from failing hearts despite reduced store Ca2+ and
RyR2 expression (Kubalova et al., 2005; Song et al., 2005). One study,
using a chronic HF model of paced right ventricle of canine heart (13–
24 months), included single channel measurements of RyR2 function
and these demonstrated increased sensitivity to luminal Ca2+
(Kubalova et al., 2005). This might provide the explanation for
increased Ca2+ spark activity despite a decreased store Ca2+ and it has
been proposed that PKA phosphorylation increases the sensitivity of
RyR2 to luminal Ca2+ (Xiao et al., 2007a).
4.1.5. Delayed after-depolarisations in heart failure
There is sufﬁcient evidence, particularly from experimental models
to suggest that RyR2 function inHF is perturbed and that diastolic leak is
a feature of HF even if there is no agreement on the precise mechanism
of dysfunction. These changes in RyR2 function inHF take place against a
greatly modiﬁed cellular landscape, which could also contribute to the
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tubule and junctional SR— the dyadic cleft, which is so important to the
electrophysiological homeostasis of the heart beat can become
disrupted in HF (Balijepalli et al., 2003; Izu et al., 2006; Song et al.,
2006; Bito et al., 2008; Chen-Izu et al., 2007). Co-localisation between
RyR2 and LCC is disturbed as T-tubules are lost from the Z-line positions
leaving junctional RyR2 ‘orphaned’ (Song et al., 2006). This will have
serious repercussions for the critical interplay between RyR2 activation
and retrograde Ca2+ dependent inactivation of LCC (from RyR2 Ca2+
release), as seen in a detubulated myocyte model (Brette et al., 2004).
The ratio of RyR2 to LCC was altered in one study (Milnes & MacLeod,
2001) and a functional uncoupling was proposed in another, where the
ratio remained the same (Gomez et al., 1997). The interaction between
the other ion channels and exchangerswhich contribute to theAP (NCX,
K+andNa+channels and theNa+/K+ATPase) that interact functionally
through the Ca2+, K+ and Na+ ionic changes in the dyadic cleft will also
be compromised by such structural changes.
APduration is increased inhumanHF(Davia et al., 2001;Kogler et al.,
2003; Stagg et al., 2004) and animal models (Huang et al., 2000;Milnes
&MacLeod, 2001; Perrier et al., 2004). Electrical remodelling and down
regulation of K+ channels occurs early in the development of
hypertrophy (Huanget al., 2000; Perrieret al., 2004).Adown-regulation
of the transient outward current Ito and a decrease in mRNA for the K+
channel Kv4.2 has been reported thatmay involve a central role for LCC in
regulation of gene expression (Perrier et al., 2004). However, LCC
protein expression itself, in most studies, is unchanged in HF (Richard
et al., 2006). Many studies show upregulation of NCX expression two or
three fold (Hasenfuss et al., 1994; Reinecke et al., 1996; O'Rourke et al.,
1999; Schwinger et al., 1999b; Pogwizd, 2000; Litwin & Zhang, 2002).
The inward rectifying K+ current (IKI) normally stabilises the resting Em
but its activity is reduced by Ca2+ (Fauconnier et al., 2005). The
increaseddiastolic leakof Ca2+ inHFmaycontribute todestabilisationof
Em and together with the increase in NCX could lower the threshold for
DADs, so that even a modest diastolic leak from RyR2 may result in an
increased propensity to trigger a fatal arrhythmia (Pogwizd & Bers,
2002; Scoote &Williams, 2004; Fauconnier et al., 2005; Sipido & Eisner,
2005).
4.2. Catecholaminergic polymorphic ventricular tachycardia
4.2.1. Clinical presentation and genotype
There are a number of inherited arrhythmias affecting ion channel
function (Lehnart et al., 2007). CPVT is a rare, inheritable autosomal
dominant condition (Mohamed et al., 2007), which was described
before genotyping became available, in patients with family members
who developed tachyarrhythmic episodes associated with emotional
stress or exercise or had died suddenly (Priori et al., 2002) often in
childhood or adolescence (Coumel et al., 1978). It is associated with a
30–35% death rate by the age of 30 (Priori et al., 2002). The ﬁrst
mutations in the RyR2 gene found to be associated with CPVT1 were
described in 2001 (Priori et al., 2001), althoughCPVT1hadbeenmapped
to the chromosome 1 1q42–q43 locus in 1999 (Swan et al., 1999). 69
point mutations were identiﬁed in the RyR2 gene in 253 (out of 915)
patients screened for CPVT1 and this number is growing as more
patients are genotyped — a current list of mutations is available on the
ESC ‘Gene connection for the heart’ data base (http://www.fsm.it/
cardmoc). Someof these RyR2mutations have been identiﬁed inpatient
groups screened for Long QT syndrome (Tester et al., 2005b),
arrythmogenic right ventricular cardiomyopathy type 2 (ARVD2), in
which there is histological evidence of ﬁbrofatty streaks in the right
ventricle and the tachycardia exhibits polymorphic characteristics (Tiso
et al., 2001; Moric-Janiszewska & Markiewicz-Loskot, 2007) and
unexplained drowning on post mortem (Tester et al., 2005a). In
addition, a few patients have been identiﬁed with CPVT symptoms but
have mutations in the RyR2 luminal modulator protein calsequestrin,
Casq2 gene (CPVT2) which is linked to chromosome1p13–p21 butthese patients have an autosomal recessive phenotype (Lahat et al.,
2001b; Postma et al., 2005; Terentyev et al., 2006).
The arrhythmia displayed by CPVT patients is characterised in the
ECG by a distinctive bidirectional ventricular tachycardia or poly-
morphic ventricular premature beats that occur with stress or exercise
but which are not associated with a prolonged QT interval (Leenhardt
et al., 1995; Priori et al., 2002; Postma et al., 2005), although two
studies show that the resting ECG may show lower QT intervals
(Tester et al., 2005b). A slower heart rate may also be typical
(Leenhardt et al., 1995) and was observed when compared with both
non carriers within a family and unrelated controls (Sumitomo et al.,
2003; Postma et al., 2005).
CPVT is a relatively rare disease estimated to account for ∼6000
unexplained SCDs (with no underlying cardiac pathology) in Europe
and the USA annually (George et al., 2006). The numbers of patients
with a known genotype are currently small. Nonetheless patterns are
emerging as to the criteria for diagnosis (Napolitano & Priori, 2002;
Sumitomo et al., 2003; Napolitano et al., 2005; Postma et al., 2005)
and treatment of CPVT (Napolitano et al., 2006), aetiopathology
(Chugh et al., 2004; George et al., 2006) and molecular genetics
(Napolitano & Priori, 2002). This section will concentrate on the
molecular mechanisms, which underlie the phenotype.
4.2.2. Catecholaminergic polymorphic
ventricular tachycardia-1 mutational clusters
The RyR2 point mutations are traditionally grouped into three
regionsof theRyRmoleculeN-terminus, central domain andC-terminus
clusters which are largely homologous to similar groups of point
mutations in the RyR1 gene (see Dirksen & Avila, 2002, for a list of RyR1
mutations). There is structural/functional evidence to split the C
terminus mutational cluster in RyR2 into two regions as discussed
later (George et al., 2006). See Fig. 4 for a diagrammatic representation
of these mutational clusters spaced on the RyR2 sequence.
The ﬁrst RyR point mutation was detected in the skeletal muscle
RyR1 isoform a decade earlier than the RyR2 counterparts and this
was the R615C mutation causing porcine stress syndrome (Fujii et al.,
1991). Many mutations of RyR1 have now been linked to the human
counterparts of this condition — malignant hyperthermia (MH) and
central core disease (CCD) (MacLennan et al., 1990; Chen et al., 1993;
Quane et al., 1993), which can have overlapping phenotypes (Frank
et al., 1980; Dirksen & Avila, 2002). MH manifests itself as an extreme
reaction to volatile anaesthetics, such as halothane and muscle
relaxants such as succinylcholine, resulting in rapid onset of muscle
rigidity, unstable and increasing blood pressure and high temperature,
and CCD with muscle weakness and characteristic remodelling of
skeletal muscle sarcomeres seen in histological sections (Dirksen &
Avila, 2002).
Using SR from human biopsy of a carrier of the G2434R mutation,
ryanodine binding studies showed the mutant channel to have an
increased sensitivity to caffeine and 4-chloro-m-creosol and a reduced
sensitivity to inhibiting concentrations of Ca2+ and calmodulin
(Richter et al., 1997). The testing of muscle strips with caffeine and
halothane was developed as the in vitro contracture test (IVCT) a
diagnostic test for MH although genetic screening is now also
available (Urwyler et al., 2001). Most experimental models of MH
and CCD involve the transient expression of mutant RyR1 in HEK293
or dyspedic muscle cells (Tong et al., 1999; Dirksen & Avila, 2004) and
much of the data is consistent with the human study— namely that SR
Ca2+ leak of varying severity is associated with the MH and the MH
plus CCD phenotype, although uncoupling of activation of RyR from
allosteric activation by LCC and a resultant reduction of Ca2+ release is
a feature of some CCD mutations (Avila et al., 2001). To explain the
relative severity of mutations associated withMH, MH+CCD and CCD
a schematic, based on the characteristics of a number of point
mutations expressed in dyspedic myotubes has been proposed
(Dirksen & Avila, 2004). The MH mutations showed an increase in
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activation (voltage sensitive Ca2+ release). Those associated with the
MH plus CCD, in addition, showed underlying SR Ca2+ store depletion
and CCD mutations had SR Ca2+ store depletion but also a decreased
response to activation — EC uncoupling (Dirksen & Avila, 2004). The
mutations and their severity did not strictly segregatewithin the three
deﬁned clusters although mutations associated with CCD (33 out of
44) tended to be in the C-terminus region (Lynch et al., 1999; Monnier
et al., 2001), however the CCD phenotype was also seen in a few
mutations in the N-terminus and central domain clusters (Quane
et al., 1993; Zhang et al., 1993; Dirksen & Avila, 2004; Xu et al., 2006)
(for reviews onMH and CDD refer to Dirksen & Avila (2002), Dulhunty
et al. (2006), and Robinson et al. (2006)).
The observations for RyR1 can be generally translated to RyR2
allowing for the fact that CICR is the only mechanism of activation of
RyR2 and not a direct allosteric interactionwith LCC. Only a few of the
RyR2 mutations identiﬁed in patients have been characterised.
However those which have mostly exhibit gain of function features
which can broadly be deﬁned as an increased open probability in
response to activation by caffeine, 4-chloro-m-creosol or phosphor-
ylation compared to WT.
Twomodels of knock-in mice have been created carrying the CVPT1
mutations R4496C (humanmutation R4497C) (Cerrone et al., 2005; Liu
et al., 2006) and the ARVD2 mutation R176Q (Kannankeril et al., 2006).
Both models showed normal function at rest but arrhythmic episodes
were provoked by isoproterenol or caffeine and epinephrine adminis-
tration. Isolated cardiomyocytes from the R176Q mice showed an
increased numbers of spontaneous Ca2+ oscillations even at rest and a
mixture of aberrant Ca2+ transients, when stimulated with isoproter-
enol, consistent with the generation of DADs but SR store Ca2+ was
unaltered (Kannankeril et al., 2006). The R4496C mutation also
exhibited DADs in paced myocytes, which, in the presence of
isoproterenol, increased and were sustained after cessation of pacing
(the WT also showed some DAD activity with isoproterenol but only
when paced) (Liu et al., 2006). The R176Q mutation showed no
histological evidence typical of human ARVD2 changes in the right
ventricle but there was evidence of cardiomyopathy, in 1 year old mice,
in the form of decreased end-diastolic volume of the right and left
ventricles and higher end-diastolic pressure in the left ventricle
(Kannankeril et al., 2006). Epicardial and endocardial optical mapping
suggested that the arrhythmias originated fromHis-Pukinje networks in
the right ventricle and/or the left ventricle in the R4496C mouse and in
addition single isolated Purkinje cells demonstrated DADs evenwithout
stimulation by isoproterenol (Cerrone et al., 2007). This work also
addressed various patterns of arrhythmia seen on ECG and the focal
origin within the conduction system provided an explanation for the
transitions between biventricular, polymorphic and ventricular ﬁbrilla-
tion characteristic of CPVT (Cerrone et al., 2007).
The CPVT2 CSQ D307H knock-in mouse model had structurally
normal hearts and ventricular function (Dirksen et al., 2007). There
were no changes in the expression of other ECC proteins, although the
levels ofmutant CSQ variedwith individual transgenic lines showing up
to 6 fold expression. Myocytes displayed an increase in spark frequency
and a decrease in spark amplitude and in the presence of caffeine, the
addition of isoproterenol invoked spontaneous Ca2+ transients. ECG
registered complex ventricular arrhythmias when isoproterenol (with
or without caffeine) was administered (Dirksen et al., 2007).
Thus, the knock-in mouse models largely conﬁrm the human
phenotypes that are associated with RyR2 mutant dysfunction, and
support the view that a trigger, such as exercise or emotional stress,
(isoprenaline or caffeine plus epinephrine in mouse models) could
evoke DADs (Nakajima et al., 1997).
4.2.3. Molecular mechanisms of ryanodine receptor dysfunction
The sub-cellular manifestation of increased adrenergic drive is PKA
phosphorylation of key ECC proteins (including RyR2), which causechanges in the RyR2 microdomain environment as outlined above in
Section 2.4. The ﬁnding that CSQ mutants also cause the CPVT2
phenotypeputs the focus onaberrant Ca2+signalling, translated through
RyR2 modulation and possibly manifest through SR store Ca2+
concentrations. Simulations of CPVT1 and CPVT2 have tested some of
these proposed mechanisms, which might underlie abnormal Ca2+
homeostasis. Thesemodels were able to predict DADs (in response to
β-adrenergic stimulation) induced by impaired luminal Ca2+ sensing
in CPVT2 (Faber & Rudy, 2007; Iyer et al., 2007) and also consistent
with store-overload-induced Ca2+ release (SOICR) in CPVT1 (Iyer et
al., 2007). Impaired coupled gating, due to reduced FKBP12.6 binding
to RyR2, could also produce simulated DADs (Iyer et al., 2007). Thus
some proposed mechanisms for dysfunction are emerging and the
molecular characterisation of the individual CPVT mutations are
discussed within the context of these.
4.2.3.1. Ryanodine receptor interdomain interactions. Several obser-
vations have led to the hypothesis that the clusters of RyR1/2 point
mutations may be coincident with one or more domain interactions.
In CPVT, mutations fall into the N-terminus or central domain clusters,
which make up the proposed interacting zipper domains (Yamamoto
& Ikemoto, 2002) or into the C-terminus domain, which is divided into
the ‘I-domain' and the transmembrane region (George et al., 2004). It
is proposed that a mutation in any of the domains would weaken the
interaction with its partner thus causing instability and loss of ﬁdelity
of channel gating.
4.2.3.1.1. Zipper domain. The synthetic peptide DP4 (2442–2477
of RyR1) was able to disrupt the zipper domain interaction, whereas
DP4 with the R2458C MH mutation had no effect (Yamamoto et al.,
2000). When introduced into permeabilised frog skeletal muscle
ﬁbres peptide DP4 increased Ca2+ spark frequency but DP4 (R2458C)
had no such effect (Shtifman et al., 2002). The DP4 peptide was also
able to increase ryanodine binding in SR vesicles but DP4 peptides
containing the mutations R2452W, I2453T, R2454C, R2454W, R2458C
or R2458H all showed greatly reduced activation (Bannister et al.,
2006). NMR analysis of DP4 showed it to comprise two helical regions
with the cluster of MH mutations (R2452W, I2453T, R2454C, R2458C
or R2458H located at the C-terminus of the ﬁrst helix or in the loop
connecting the two helices (Bannister et al., 2006). It was shown,
using a similar peptide DPc10 (G2460–P2495), for RyR2 studies
(Yamamoto & Ikemoto, 2002) containing the CPVT mutation R2474S
(Priori et al., 2001) that the WT peptide increased the sensitivity to
activating Ca2+ and increased ryanodine binding but DPc10M
(R2474S) had no effect (Yamamoto & Ikemoto, 2002). The implication
from these studies was that a RyR point mutation, introduced to a
modulatory peptide, could render it incapable of normal domain
interaction.
4.2.3.1.2. I-domain. The C-terminus cluster of CPVTmutations can
be sub-divided into two regions 3534–4610 (the I-domain (George
et al., 2004)) and 4497–4959 (the transmembrane/pore region
(Williams et al., 2001; Du et al., 2002)). Using a fusion protein com-
plementation approach and FRETanalysis it was demonstrated that an
N terminus − 4610 construct containing the I-domain and labelled
with DsRed could regulate the RyR2 C-terminus, tagged with GFP (the
latter expressed in CHO cells in an induceable system) and could
restore caffeine sensitivity. A CPVT mutation either in the N-terminus
construct (S2246L) or in the C-terminus (N4104K or R4497C) showed
similar basal regulation of Ca2+ when expressed in CHO cells.
However, when challenged with caffeine all of the mutant constructs
showed an increased sensitivity (George et al., 2006). Noise analysis,
of the FRET signal, distinguished the two C-terminus mutations from
that in the N-terminus construct and was attributed to instabilities in
the I-domain regulation of the C-terminus. These effects were also
observed when the noise analysis was extended to the mutant
channels expressed in HL-1 cells (cardiac phenotype) indicating that
the instabilities were attributable to the RyR2 protein itself and not to
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The I-domain/C-terminus interaction was explored in RyR1 using
theDP15 (4821–4841) peptide (Hamada et al., 2007) corresponding to
the putative cytoplasmic loop connecting transmembrane regions 6
and 7 (Dumodel (Du et al., 2002)). Activation of RyR1 byDP15was lost
when the L4823P or L4837V MH causing mutations were introduced
(shown in ryanodine binding experiments). The corresponding I-
domain interaction site was a 92 kDa fragment of RyR1, which was
recognised by an anti-RyR1 site-speciﬁc Ab to 4114–4142. In analogy to
the effect of DPc10 on the ‘zipper domain’ interaction it was proposed
that the I-domain/C-terminus interaction stabilises the closed channel
and this is compromised by point mutations (Hamada et al., 2007).
4.2.3.2. Regulation by FKBP12.6. It has been proposed that a CPVT
mutation alters FKBP12.6 binding characteristics. CPVT mutations
(S2246L, R2474S or R4497C (Wehrens et al., 2003) or P2328S, Q4201R
or V4653F (Lehnart et al., 2004)) were co-transfected with FKBP12.6
into HEK293 cells. All mutants exhibited normal single channel
properties with 150 nM Ca2+ in the cis chamber but PKA phosphor-
ylation increased the Po of all channels and some sub-conductance
states were seen. The mutants were also more sensitive to activating
Ca2+ concentrations (S2246L, R2474S or R4497C (Wehrens et al.,
2003)) and P2328S (Lehnart et al., 2004) and inhibition by Mg2+ was
reduced (P2328S, Q4201R or V4653F (Lehnart et al., 2004)). The
mutant channels all showed reduced (2 fold) afﬁnity for FKBP12.6,
which did not alter their single channel activity at rest, but was
manifest only when the channels were phosphorylated (Wehrens et
al., 2003; Lehnart et al., 2004). The ‘sticky’ FKBP12.6 D37S mutant
could bind to both WT and the R2474S mutant even when
phosphorylated and reduce Po to WT non-phosphorylated levels
suggesting that deﬁcient FKBP12.6 binding was part of the CPVT
mechanism (Wehrens et al., 2003).
4.2.3.3. Catecholaminergic polymorphic ventricular tachycardia-1 and
regulation by luminal Ca2+. The SOICR (store overload induced Ca2+
release) hypothesis postulates that the aberrant feature of CPVT
mutations is an enhanced sensitivity to luminal Ca2+ concentration
(Jiang et al., 2004, 2005). A number of mutations were examined by
expression in HEK293 cells— C-terminus mutations N4104K, Q4201R,
R4496C, I4867M and N4895D, central domain mutants S2246L and
R2474S and N terminus mutants R176Q/T2504M and L433P (Jiang
et al., 2004, 2005). All mutations increase the frequency of
spontaneous Ca2+ oscillations seen in both HEK293 cells (Jiang
et al., 2004, 2005) and those which were also examined in HL-1 cells
(R176Q/T2504M, R2474S and Q4201R (Jiang et al., 2005)). Single
channel studies revealed that the mutants all displayed an increased
sensitivity to luminal Ca2+, although the two N terminus mutations
were 10-fold less sensitive than the others (Jiang et al., 2005). The
mutants all had a lower threshold for spontaneous Ca2+ release
(oscillations) when store load was varied with extracellular Ca2+ and
the cells expressing the mutants all exhibited a reduced Ca2+ store
content compared to WT (Jiang et al., 2005). The latter observation,
whilst not invalidating the concept of increased sensitivity to luminal
Ca2+ as part of the mechanism, does question the suitability of store
‘over’ load in the acronym for the hypothesis, even though as has been
discussed above store overload can cause DADs (Diaz et al., 2004).
There was no evidence of increased sensitivity to activating Ca2+ as
ryanodine binding dose response curves to Ca2+ were essentially the
same as WT. The increased response to luminal Ca2+ in the RyR2
mutants was not related to regulation by the CSQ complex since this is
not expressed in HEK293 cells.
4.2.3.4. Catecholaminergic polymorphic ventricular tachycardia-2 and
regulation by luminal Ca2+. The CSQmutations, which also cause the
CPVT phenotype, have provided further insight into the proposedmechanism of regulation of RyR2 sensitivity to luminal Ca2+ via the
CSQ/triadin/junctin complex. The CSQ mutant, with a D307H
substitution, was characterised by adenoviral expression in rat
myocytes and showed a reduced Ca2+ storage capacity and reduced
spontaneous Ca2+ sparks (Viatchenko-Karpinski et al., 2004).
Furthermore when paced and exposed to isoproterenol the myocytes
displayed arrhythmic behaviour. Dialysis of the myocyte with citrate
buffer, to reduce the SR store Ca2+ concentration, eliminated these
extrasystolic transients (Viatchenko-Karpinski et al., 2004). A sig-
niﬁcant conformational change in the D307H protein structure was
demonstrated, which may have contributed to both a reduced Ca2+
binding capacity and Ca2+-dependent binding to triadin and junctin
(Houle et al., 2004). A knock-in mouse model of the D307H mutation
caused CPVT. Myocytes from these animals were morphologically
different from the WT including junctional SR of greater width and
volume. Expression levels were also 2–6 fold higher than WT,
although SR Ca2+ stores and NCX activity were unchanged. Whole
cell patch clamp measurements showed changes in Ca2+ spark
frequency, Ca2+ transients and Ca2+ current when challenged with
isoproterenol and the membrane potential traces showed DADs
(Dirksen et al., 2007).
Similar characterisation of an R33Q mutant showed that it had
comparable Ca2+ binding capacity to the WT but when paced and
exposed to isoproterenol myocytes displayed arrhythmic behaviour
(Terentyev et al., 2006). Single channel studies revealed that R33Q
lacked the ability to inhibit RyR2 regulation at low luminal Ca2+
concentrations suggesting that the mutation disrupted the regulatory
association with RyR2 (via triadin and junctin) in some way
(Terentyev et al., 2006). The underlying mechanism causing CPVT
and RyR dysfunction in CSQ mutants could be altered Ca2+ buffering
in the SR and susceptibility to luminal Ca2+ changes and/or
dysregulation of RyR by the CSQ/junctin/triadin/complex (Bassani
& Bassani, 2007; Gyorke & Terentyev, 2008). A junctin knock-out
mouse had a high incidence of mortality (25% at three months despite
structurally normal hearts) and when stimulated with isoproterenol
demonstrated DADs (Yuan et al., 2007). Over expression of triadin in
myocytes also caused arrhythmia (Terentyev et al., 2005; Kirchhof
et al., 2007). These genesmay be additional loci inwhich CPVTcausing
mutations might be found in the future.
4.2.3.5. Cytoplasmic Ca2+ sensitivity. Caffeine sensitises RyR2 to
activator Ca2+ and increases Po in bilayers and in ryanodine binding
assays (Meissner, 2002). MH mutations in RyR1 display enhanced
caffeine sensitivity (Avila, 2005). RyR2, puriﬁed from an arrhythmo-
genic right ventricular cardiomyopathy (ARVC) patient heterozygous
for G1885E/G1886 and G1885/G1886S, was compared for single
channel characteristics to an ARVC patient with a RyR2 WT genotype,
but whose heart was removed for transplant for cardiomyopathy
(Milting et al., 2006). The mutant channels displayed sub-conduc-
tance states and at the lowest conductive state displayed a greatly
enhanced Po at pCa7.7, compared to WT (although RyR2 activity of
this control may have been compromised by the cardiomyopathy
(Milting et al., 2006). This suggested that increased sensitivity to
cytosolic Ca2+ maybe the underlying dysfunction of RyR2 for this
mutation. An increased sensitivity to Ca2+ and caffeine was demon-
strated for S2246L, N4104K and R4497C mutations expressed in
HEK293 cells or HL-1 cells, where it was also shown that there was no
change in SR store Ca2+, which might have accounted for enhanced
Ca2+ release (George et al., 2006). The characteristics of caffeine-
dependent Ca2+ release varied greatly when N-terminus and central
domain mutations were expressed in HEK293 cells (L433P, N2386I,
R176Q, T2504M and R176Q/T2504M) (Thomas et al., 2004, 2005).
N2386I and R176Q/T2504M showed greater sensitivity to caffeine at
resting Ca2+. L433P, T2504 and R176Q/T2504M showed a profound
loss of Ca2+ sensitive inhibition and SR store Ca2+ was unchanged in
these experiments. However, others reported increased Ca2+ sparks
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(Jiang et al., 2005). Mouse R4496C (equivalent to human R4497C) was
expressed in HEK293 cells and these showed a greater incidence of
spontaneous Ca2+ release than cells expressing WTmRyR2. Increased
basal channel activity was observed in both single channel studies and
ryanodine binding experiments and the R4496C mutation showed a
greater sensitivity to Ca2+ and caffeine (Jiang et al., 2002a).
4.2.4. Consensus view of mutant characterisation
CPVT patients show a spectrum of phenotypic severity including a
symptom-free cohort of carriers sharing the same genotype as
symptomatic patients (Priori et al., 2002; Postma et al., 2005; Tester
et al., 2005b). Possible reasons for this could be ‘rescue’byco-expression
of a polymorphism (Milting et al., 2006) or imprintingwhere amutated
gene from an affected adult is ‘silenced’ in an offspring and only the
normal allele is expressed, as for RyR1mutations (Zhou et al., 2006). It is
proposed that the individualmutationsmay have differentmechanisms
bywhich theydisrupt channel function (Thomas et al., 2005). Looking at
the nature of the substituted amino acids suggests that there are
differentways inwhich theymay alter RyR function. Loss or insertion of
a proline (P) a secondary structure helix breaker may disrupt protein
folding. One such mutant — L433P, in separate but comparable studies
using expression in HEK293 cells, showed altered caffeine-dependent
activation in one (Thomas et al., 2004, 2005), but paradoxically
increased Ca2+ spark activity and response to caffeine and increased
sensitivity to luminal Ca2+ in another (Jiang et al., 2005) The reasons for
this discrepancy are unclear at present. Nuclear magnetic resonance
analysis of the peptide probe DP4 showed it to have two helical regions
with a cluster of MH mutations (R2542W, I2453T, R2454C, R2458H or
R2458C) located at the C-terminus of the ﬁrst helix or in the loop
connecting the two helices, suggesting a possible structural alteration in
the relationship between the twohelical regions (Bannister et al., 2006).
Loss, addition or the swapping of charge on a residue could have
implications for protein–protein interactions. In this respect it has been
shown for themouse R4496Cmutation, expressed in HEK293 cells, that
R4496E enhanced the characteristics shown by the mutant, whereas
R4496K, which reversed the charge, showed the same characteristics as
WT (Jiang et al., 2002a). The substitution or loss of serine (S) or
threonine (T) residues have implications for phosphorylation and3 such
residues are lost and 12 created amongst the reported mutations
(Thomas et al., 2006). It is suggested that the G1886S substitution
creates a protein kinase C phosphorylation site (Milting et al., 2006).
These considerations make it difﬁcult to foresee a common molecular
mechanism of dysfunction.
4.2.5. Delayed after-depolarisations in
catecholaminergic polymorphic ventricular tachycardia
The reports of normal function of hearts at rest suggest that there is
no long-term change in the expression of the proteins that participate
in maintaining the normal AP in CPVT. However, in ARVD2 patients
there is some evidence of tissue remodelling of the right ventricle and
one knock-in mouse model had some symptoms of cardiomyopathy
(Kannankeril et al., 2006). Some patients with an abnormal ECG at
rest have been reported (Tester et al., 2005b) and a slowed heart rate
is also characteristic of CPVT (Choi et al., 2004; Postma et al., 2005), all
of which suggests some modest compensation in some patients.
However, there is no current experimental evidence to suppose that
factors external to RyR2 function might contribute to DADs, as is the
case in HF (see Section 4.1.4).
5. Therapy for heart failure and
catecholaminergic polymorphic ventricular tachycardia
HFusually follows an increaseddemand (load),which cannot bemet
by the available healthy heart tissue. Without means of healing or
replacing tissue damaged or lost, for example following a myocardialinfarction (asmight one day be possiblewith stem cell replacement) the
best options currently available are to sustain the functional capacity of
surviving tissue for as long as possible. The cells in this tissue, including
the cardiomyocyte, are not passive bystanders. They bring to bear a
veritable arsenal of genetic pathways intended for development, cell
maintenance or short-term physiological ﬂexibility but not ‘designed’ to
mend a ‘broken’ heart (Swynghedauw, 2006). This striving to remodel
the structural and functional components of the cell (and the whole
organ) eventually leads to inappropriate compensation and ultimately
ends in death either through pump failure or arrhythmia. Strategies for
pharmaceutical intervention are to reduce theworkload required of the
heart and to improve the output.
Untreated, the mortality for CPVT is high (∼30% by the age of 30)
with sudden death the ﬁrst symptom in some instances (Priori et al.,
2002). The genetics of CPVT have only recently been characterised and
the familial pattern of inheritance and genetic screening has now
enabled early diagnosis and speciﬁc treatment (Sumitomo et al., 2003;
Napolitano et al., 2006). CPVT, which is essentially a disease of
dysfunctional RyR2 activity, does not result in HF. It seems that
arrhythmic episodes are not sufﬁcient to destabilise the ECC ﬁdelity in
the long term even if they are not tolerated in the face of stress. The
difference between HF and CPVT phenotypes suggests that RyR2
dysfunction is a likely consequence of the progression of HF, and not
its cause. However, the link to DADs and fatal arrhythmia, as a result of
RyR2 dysfunction in both conditions, merits the question as to whether
strategies to improve RyR2 function may be of any beneﬁt (Dulhunty
et al., 2007; Santonastasi &Wehrens, 2007). In the treatment of HF, can
targeting RyR2 do more than just prevent fatal arrhythmia at the end
stage? Furthermore, do the dysfunctional mechanism(s) proposed for
RyR2 in HF share any similarities to those for CPVT, which might offer
insights into novel treatments for the latter?
Currently available therapeutic treatments for HF ameliorated
symptoms and slow progression. The recommended treatment for
chronic HF are angiotensin converting enzyme (ACE) inhibitor, β-
blocker and diuretic often combined, dependent upon severity of
symptoms (Weir & McMurray, 2005). β-blocker is the only pharma-
cological agent which can mollify the symptoms of CPVT and patients
who do not respond are ﬁtted with implantable deﬁbrillators
(Leenhardt et al., 1995; Priori et al., 2002). Prophylactic resynchroni-
sation therapy is also indicated for some HF patients with symptoms
of VT and ﬁtting either a pacemaker or pacemaker-deﬁbrillator in
patients hospitalised for HF showed a reduced mortality in the
following two years (Bristow et al., 2004; Feldman et al., 2005). A
canine model of HF examined the effect of cardiac resynchronisation
therapy. Treated hearts showed improvement in haemodynamic
parameters. Isolated myocytes demonstrated reversal of characteristic
markers of HF such as restitution of AP duration and resting
membrane potential, as well as a recovery in the amplitude of Ca2+
transients (Nishijima et al., 2007).
5.1. Reducing the cardiac load in heart failure
5.1.1. Left ventricular assist device
LVADs are used to support failing hearts awaiting donor transplanta-
tion. Their short-term use has been shown to reverse some of the
changes in protein expression associated with end-stage HF and to aid
recovery from the negative force frequency relationship by improving
myocyte function (Dipla et al.,1998; Heerdt et al., 2000). In particularβ-
adrenergic responsiveness was restored (Dipla et al., 1998; Ogletree-
Hughes et al., 2001). Signiﬁcant increases in PP1 levels, reduced RyR
hyperphosphorylation and increased FKBP12.6 bound (Marx et al.,
2000), increased expression of LCC (Chen et al., 2002) and SERCA
expression and function (Heerdt et al., 2000) have all been reported. The
limited use of LVADs does suggest that alleviation of load on a failing
heart can result in reverse remodellingand improveECC. This gives hope
that if a sufﬁciently effective therapeutic intervention were to be found
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of the heart may be achievable.
5.1.2. Drug therapies for reducing cardiac load
ACE inhibitors, as a ﬁrst line of therapy, do not act directly on
cardiac tissue but have a vasodilatory action and work by reducing
angiotensin II production and thereby reduce cardiac after-load and
pre-load and encourage renal blood ﬂow (Weir & McMurray, 2005).
Diuretics, by decreasing the blood volume, can further aid this process.
A group of compounds termed Ca2+-sensitizers also act to improve
contractility, ideally without increasing oxygen demand and altering
diastolic function (Brixius et al., 2005). One of these, levosimendan,
has been approved for short-term treatment of decompensated HF
and acts primarily to increase the sensitivity of troponin C to Ca2+
(Sorsa et al., 2001) but also activates ATP sensitive K+ channels and
has a consequent vasodilatory action on the coronary circulation
improving blood ﬂow (Earl & Fitzpatrick, 2005).
5.2. β-blockers and ryanodine receptor type-2 function
β-blockers are a counter-intuitive therapy for HF since theirmodus
operandi in the normal heart is to reduce contractility by preventing
phosphorylation and consequent up-regulation of ECC (Lohse et al.,
2003). Clinical trials have shown that β-blockers (bisprolol and
carvedilol) are very effective in reducing arrhythmia and slowing the
progression of HF (1994; McGavin & Keating, 2002; Poole-Wilson
et al., 2003; Hori et al., 2004). In contrast, the use of β-agonists, such
as dobutamine, to treat acute decompensation in HF, are only useful in
the short term because they can be arrhythmogenic (Lohse et al.,
2003).
In HF, the myocyte, because of the increased levels of circulating
catecholamines, has already compensated by reducing β-receptor
number (Bristow et al., 1982; Lohse et al., 2003; Tsukamoto et al.,
2007). However these compensatory mechanisms result in an unco-
ordinated state of phosphorylation as regards ECC proteins, with
hypophosphorylation of PLB (Schwinger et al., 1999a; Dash et al.,
2001; Schwinger & Frank, 2003) and hyperphosphorylation of RyR2
(Marks, 2003). The long term effect of β-blockade has broad spectrum
consequences on ECC by increasing phosphorylation of PLB, hence
increasing SERCA activity and elevating SR Ca2+ store concentrations
(MacLennan & Kranias, 2003). RyR2 hyperphosphorylation is reported
to be reduced and FKBP12.6 binding levels restored in a paced dog
model treated with propranolol (Reiken et al., 2001; Doi et al., 2002)
and in human heart muscle strips treated with carvedilol, metoprolol
or atenolol (Reiken et al., 2003b). The AT1 receptor antagonist —
valsartan, which inhibits noradrenaline release from the synaptic
pool, also restored SR function by reducing by Ca2+ leak (Tokuhisa et
al., 2006). There is evidence that patients prescribed the β-blocker
carvedilol, had improved clinical outcomes in HF — the COMET study
(Poole-Wilson et al., 2003) however, the underlying mechanism of
advantage, based on comparison with metopropol, was uncertain
when considered on the basis of relative efﬁcacy of dose and
selectivity for β-adrenergic subtype (Molenaar & Parsonage, 2005).
Animal studies with carvedilol suggest its additional effectiveness
might be ascribed to its antioxidant properties and stimulation of
SERCA gene transcription (Koitabashi et al., 2005) as observed in rat
cardiomyocytes. In a study of HF using a paced dog model, carvedilol
was able to improve end-diastolic pressure four fold. RyR2 hyperpho-
sphorylation was decreased and PP1, PP2 and FKBP12.6 association
with the RyR2 macromolecular complex was restored. Single channel
studies showed RyR2 channels with heterogeneous function from HF
tissue with increased Po but carvedilol reduced both Po and
heterogeneity (Xue et al., 2007). Results from a similar canine study
showed that low dose carvedilol (insufﬁcient to act through β-
blockade) produced antioxidant effects that rescued RyR2 domain
unzipping (Mochizuki et al., 2007).Thus there is evidence that treatment with β-blockers improves
RyR2 function along with other indicators of restitution of ECC. Their
mechanism of action may be multifactorial. One outcome appears to
restore the balance between phosphorylation/dephosphorylation that
normally regulates ECC and this includes RyR2 function (Lohse et al.,
2003). Another of the beneﬁcial mechanisms of β-blockade may be a
reduction in heart rate per se. A comparison of cilobradine (a sino atrial
node inhibitor, which acts to slow heart rate) with metopropol, in a
caninemodel of congestive HF, demonstrated improved haemodynamic
parameters and restoration of SERCA and NCX expression to normal
levels as a result of treatment (Cheng et al., 2007).
For the RyR2 CPVT mutants β-blockers (propranolol, metiletine,
nadolol, atenolol, carteolol or metopropol (Leenhardt et al., 1995; Priori
et al., 2001; Sumitomo et al., 2003; Aizawa et al., 2007) all improved
mortality and reduced arrhythmic episodes, however, in one study, a
high proportion of patients (37%) remained symptomatic (Priori et al.,
2001) and in another 23% of patients died within 10 years (Sumitomo
et al., 2003). 11 out of 13 CPVT2 patients with the CSQ mutation D307H
(Lahat et al., 2001a) and 2 out of 3 with truncation mutations (Postma
et al., 2005) were also effectively treated with propranolol. β-blockers
are unfortunately not able to help a substantial number of patients in the
long term.
5.3. Stabilising ryanodine receptor type-2 activity
5.3.1. LCC agonists and ryanodine receptor type-2 function
Intravenous verapamil had a beneﬁcial effect when given acutely
to CPVT patients already taking β-blockers and increased the heart
rate threshold at which exercise-induced arrhythmias appeared
(Swan et al., 2005). Of interest were not the effects of verapamil on
LCC activity, but the dose given was aimed at concentrations high
enough to interact with RyR2 and inhibit ryanodine binding (Valdivia
et al., 1990).
5.3.2. JTV519 (K201)
Some animal models of HF have tested a compound ﬁrst shown to
ameliorate arrhythmia associated with DADs in paced dogs (Kaneko,
1994). This compound, known as JTV519 (K201), is an analogue of
diltiazem— a LCC antagonist with a generalised spectrum of inhibition
of several types of ion channel including K+ channels and RyR2
(Balasubramaniam et al., 2005). Diltiazem, but not nifedipine,
suppressed caffeine and FK506 provoked arrhythmia in mouse hearts
and myocytes demonstrating a link with spontaneous Ca2+ release
(Balasubramaniam et al., 2005) and verapamil and diltiazem were
able to decrease arrhythmic activity in a murine model of arrhythmia,
induced by isoprenaline, (Balasubramaniam et al., 2004). The action of
JTV519 suggested that it might also target RyR2 (Yano et al., 2003;
Wehrens et al., 2004a), although like diltiazem it affects a number of
ion channels, and action on LCC, Na+ and K+ channels have also been
demonstrated (Kimura et al., 1999; Robinson et al., 2006; Loughrey
et al., 2007). It is also reported to inhibit SERCA activity (Loughrey &
Smith, 2006; Loughrey et al., 2007) and to act as anα1-adrenoreceptor
blocker (Hasumi et al., 2007).
5.3.2.1. The action of JTV519 on normal ryanodine receptor type-2
function. The effect of JTV519 is reported to involve the interaction of
RyR2with FKBP12.6 (Marks, 2002). In normal canine SR vesicles, JTV519
was shown to have no effect on SRCa2+ uptake or on ryanodine binding
(Kohno et al., 2003). Using canine SR vesicles the rate of Ca2+ leak was
unmasked by the addition of thapsigargin to inhibit the Ca2+ uptake
once the vesicle was full (Yano et al., 2003). JTV519 addition (1 µM)
had no effect on the almost negligible release rate. The rate of release
could be increased by the addition of FK506 to dissociate FKBP12.6
butwhen JTV519was addedwith FK506 therewas no such increase in
leak rate and thus it was concluded that JTV519 could stabilise the
channel in a similar way to FKBP12.6 (Yano et al., 2003). Ca2+ leak in
168 L.M. Blayney, F.A. Lai / Pharmacology & Therapeutics 123 (2009) 151–177canine SR vesicles, induced by peptide DPc10, was reversed by
JTV519. However the amount of FKBP12.6 associated with SR vesicles
was not changed by JTV519 so the inhibition of Ca2+ leak was not due
to re-association of FKBP12.6 but a direct effect of JTV519 in
stabilising the ‘zipper’ domain interaction (Oda et al., 2005). The
binding site for JTV519 has been identiﬁed in a peptide of RyR2
corresponding to 2114–2149, which may interact with the central
domain of the proposed zipper region (Yamamoto et al., 2007).When
JTV519 was added to a dose response curve, for FK506 dissociation of
FKBP12.6 from SR vesicles, 1 µM JTV519 shifted the curve marginally
to the right but no change in the kd was apparent (Yano et al., 2003).
The action of JTV519 on SOICR was found to be independent of
FKBP12.6 (Hunt et al., 2007). Spontaneous beats were found to be
suppressed in both isolated myocytes, irrespective of the presence of
FK506, and in HEK-293 cells expressing RyR2 alone or in combination
with FKBP12.6. Decreased afﬁnity for Ca2+ was also demonstrated in
ryanodine binding experiments in response to JTV519 in the absence
of FKBP12.6 (Hunt et al., 2007). Examination of the effect of JTV519 on
ECC in rabbit ventricular cardiomyocytes demonstrated a reduction
in ECC gain at 1 and 3 µM JTV519 (Loughrey et al., 2007). Increasing
store Ca2+ resulted in diastolic spontaneous Ca2+ release events,
which were reduced in frequency by JTV519 but the Ca2+ transient
amplitudewas unchanged. It was concluded that JTV519 could inhibit
both RyR2 and SERCA and that at 3 µM JTV519 also reduced ICa
through effects on LCC. There was no additional effect of JTV519 in
myocytes over-expressing FKBP12.6 (Loughrey et al., 2007). These
results mostly support the view that the action of JTV519 in reducing
the activity of the RyR2 channel is a direct one and independent of
FKBP12.6.
5.3.2.2. JTV519 and heart failure. JTV519 has been shown to have
beneﬁcial effects in ischaemia and reconditioning. JTV519 improved
energy metabolism (Kawabata et al., 2000) and the protective effects
were attributed to inhibition of the post-ischaemic rise in Ca2+
(Hachida et al., 1999; Inagaki et al., 2000b). JTV519 has also been
shown to activate PKCδ and up regulate its translocation to the plasma
membrane — a part of the preconditioning response, which is
protective in ischaemia, although the mechanism was not explored
(Inagaki et al., 2000a). JTV519 acts on annexin V a cytoskeletal protein,
which has Ca2+ binding and Ca2+ channel activity. Crystallisation of
JTV519 with annexin V suggested that it bound to a hinge region
(Kaneko et al., 1997a) and thereby inhibited Ca2+ movement (Kaneko
et al., 1997b).
The action of JTV519 has been explored extensively in the context of
the RyR2 hyperphosphorylation hypothesis. The original studies in a
paced dogmodel showed that the prophylactic administration of JTV519
prevented the haemodynamic symptoms associated with HF. The
isolated SR vesicles, from JTV519 treated animals, showed no abnormal
Ca2+ leak, which was characteristic of HF in this model, and this was
attributed to the lack of RyR2 hyperphosphorylation and the restitution
of FKBP12.6 binding to levels seen in pre-paced hearts (Yano et al.,
2003). It was uncertain whether the action of JTV519 was dependent
upon rebinding of FKBP12.6 or if the rebinding occurred as a result of
improved function of RyR2. This was speciﬁcally tested by one group
using either FKBP12.6 null or +/− heterozygous knockout mice, which
had structurally normal hearts (Wehrens et al., 2004a). The effect of
JTV519 on RyR2 single channel function in +/−mice was to reduce Po.
Po of the−/− channel in the presenceof JTV519wasgreater than thatof
the untreated +/− mouse but regrettably this was not statistically
compared to the untreated−/− control. Using programmed electrical
stimulation to evoke arrhythmia in the same mice, or measuring
spontaneous oscillations or isoprenaline-evoked Ca2+waves in isolated
myocytes, alternans, oscillation or waves could only be suppressed by
JTV519 treatment in the +/−mice but not the−/−mice. Thus it was
concluded that the presence of FKBP12.6was necessary for the action of
JTV519 (Lehnart et al., 2006) in this model.The action of JTV519 on RyR2 zipper domain interaction has been
explored in HF (Oda et al., 2005). Domain unzipping, measured using
the ﬂuorescent quencher method, and Ca2+ leak could be induced in
canine SR vesicles using SIN-1, DPc10, cAMP (phosphorylation) or
FK506 (Oda et al., 2005), both of which could be countered by JTV519
addition (Yano et al., 2005). In normal myocytes SIN-1 reduced cell
shortening and decreased the peak Ca2+ transient and increased its
duration. These effects were reversed by JTV519 (and the antioxidant
edaravone — see Section 4.1.3) in a paced dog model (Yano et al.,
2005).
JTV519 in animal models is clearly able to protect against the onset
of HF but, although many studies have focussed on the changes
associated with RyR2 function, it is not clear whether it acts
speciﬁcally on RyR2 or through a broad spectrum of pharmacological
activity against ion channels within the myocyte (Lehnart et al.,
2005a). In addition to its action on the heart, JTV519 treatment had
favourable effects in other tissues, which may contribute to the
alleviation of symptoms in HF. It reversed hyperphosphorylation and
promoted rebinding of FKBP12 to RyR1 in skeletal muscle, improving
peripheral muscle function and relieving the fatigue associated with
HF (Reiken et al., 2003a; Ward et al., 2003). JTV519 also enhanced
renal haemodynamic and excretory properties by reducing haemo-
dynamic load, an action ascribed to its effects on RyR2 expressed in
kidney (Lisy & Burnett, 2006). Pulmonary veins have been implicated
as a source of ectopic beats initiating atrial ﬁbrillation. Experiments
with isolated pulmonary vein myocytes showed JTV519 to be an anti-
arrhythmic (Chen et al., 2008).
5.3.2.3. JTV519 and catecholaminergic polymorphic ventricular
tachycardia. JTV519 did not prevent arrhythmic episodes in the
CPVT R4496C knock-in mouse (Liu et al., 2006). There has been one
report that JTV519 can restore single channel function of CPVT mutant
P2328S expressed in HEK293 cells. When phosphorylated by PKA in
single channel studies the addition of JTV519 reduced Po to that of WT,
but unfortunately this study, which also included two C-terminus
mutations, did not report any results for JTV519 on these (Lehnart et al.,
2004). The P2328S mutation falls in the postulated zipper domain, and
JTV519 has been shown to be effective in reversing the effects of DPc10
peptide-induced domain unzipping and in reversing the unzipped state
of this domain inHF (Oda et al., 2005) andwhen the domain is unzipped
by oxidation (Yano et al., 2005). Similar experiments using peptides to
the N-terminus and C-terminus, spanning the respective R176Q or
N4104K ARVD2 mutations, showed that JTV519 could reduce the
incidence of DADs and reduce the frequency of Ca2+ sparks for the N
terminus peptide but not for the C terminus (Tateishi et al., 2007). These
experiments point at the possibility that JTV519 could be effective
against CPVT mutations in the central zipper domain or its postulated
interacting domain at theN-terminus and thereby beneﬁt a select group
of patients.
5.3.2.4. Future therapies and ryanodine receptor type-2 stabilisation.
Restored SR Ca2+ content is a marker of HF reversal in many models.
Strategies to speciﬁcally target proteins concerned with increasing SR
Ca2+ store content have all shown beneﬁcial effects in ameliorating
HF symptoms in animal models. These include over-expression of
SERCA2a (Giordano et al., 1997; Baker et al., 1998; del Monte et al.,
1999; Miyamoto et al., 2000; del Monte et al., 2001), ablation of PLB
by antisense RNA (He et al., 1999; Eizema et al., 2000) and
overexpression of phosphatase inhibitor P-1 to inhibit PP1 and
enhance PLB phosphorylation (Pathak et al., 2005). Manipulating
the expression of these proteins all represent potential targets for
novel therapies. There is no reasonwhy targeting RyR2 to stabilise the
channel, both preventing diastolic Ca2+ release and increasing the SR
Ca2+ store content should not be equally as effective (Dibb et al.,
2007). It has been shown by using tetracaine, a RyR inhibitor, that
reducing the Po of RyR2 also reduces alternans (arrhythmic
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myocytes isolated from a canine model of HF, the observed reduction
in Ca2+ store content could be reversed by the application of the RyR2
channel blocker ruthenium red (Belevych et al., 2007). JTV519 is
currently in clinical trials for HF and it will be important to know if this
fulﬁls the promise suggested by the animal studies. Analogues of
JTV519, which maybe more RyR2-speciﬁc are in development
(Lehnart et al., 2005a) and it will be interesting to observe if these
are as effective in HF as their broad spectrum parent.
There is a range of severity in the phenotypic symptoms of CPVT
and evenwithin consanguineous families carrying the same mutation
some probands can be symptom-free (Postma et al., 2005). The
reasons for this are unclear. At the molecular level both CPVT1 and
CPVT2 cause instabilities in RyR2 channel gating which lead to
diastolic leak, which can be provoked experimentally by activation of
RyR2 with pharmacological agents or exercise. There are clearly
observable differences in the characteristics of individual mutations
expressed in isolated cells, with possible different underlying
mechanisms of RyR2 instability proposed (Thomas et al., 2006). So
could an Ehrlich's ‘magic bullet’ exist for CPVT? — with ∼30% of
patients intractable to β-blocker therapy one is certainly needed
(Priori & Napolitano, 2005). A good example of such a bullet is the
RyR1 inhibitory drug dantrolene. The RyR1 mutations show the same
miscellany of substitution and clustered distribution as those for RyR2.
By some fortuitous quirk, perhaps of molecular folding surrounding
the binding site, and despite sharing an identical protein sequence for
the proposed binding region (RyR1 L590-C609 and RyR2 L601-C619)
(Palnitkar et al., 1999) dantrolene was thought to only affect RyR1
(Zhao et al., 2001). The binding site is outside of the N-terminus
cluster of mutations (but able to stabilise zipper domain interactions)
(Kobayashi et al., 2005). Importantly, its use to treat acute MH has
reduced mortality to b10%, which suggests that its action is generic
and effective against most of the MH mutations (Krause et al., 2004;
Rosenberg et al., 2007). It has now been reported that dantrolene
cannot only bind to RyR2 but pretreatment can prevent ventricular
tachycardia induced by epinephrine or exercise in mice with the
R2474S knock-in CPVT mutation and prevent DADs in cardiomyocytes
from these mice (Kobayashi et al., 2007). The relative potency of
dantrolene for RyR1 versus RyR2 was not given.
Using existing therapies against the backdrop of knowledge of the
mechanisms underlying RyR2 dysfunction allows for a strategic
approach with potential new therapeutic compounds. JTV519 shows
promise for HF but we do not know enough about its speciﬁcity of
action on RyR2 nor have there been sufﬁcient studies of its efﬁcacy to
know whether this promise extends to treatment of some CPVT
mutations.
6. Ryanodine receptor type-2
arrhythmic mechanisms — reconciling
structure, function and therapeutic targets
Overall ECC exhibits a tremendous capacity for compensatory
regulation and is remarkably resilient both under normal physiolo-
gical conditions and in the face of pathological assault and the same is
true for RyR2. Although RyR2 has an inherent molecular defect in
CPVT1, the ﬁnding of a similar phenotype in CPVT2 (CSQ mutation)
suggests that RyR2 dysfunction is similarly compromised by dysre-
gulation as also suggested in end-stage HF. The demise of RyR2 in both
HF and CPVT have been considered jointly in this review, not least
because RyR2 dysfunction, resulting in the diastolic leak and
arrhythmia (DADs) in both conditions provide important clues to
the underlying regulation and channel gating of RyR2 and its
relationship to its microdomain environment. The understanding of
these processes will provide the basis for therapeutic strategies.
Several mechanisms have been postulated to underlie dysfunction,
perhaps they should be considered, not as mutually exclusive, but as ifthey form part of a continuum that underlies the regulation of RyR
channel gating. It would not be difﬁcult to construct a working
hypothesis which relates molecular movement with channel (dys)
function. When the channel is activated by Ca2+ this might result in a
molecular reorganisation of the regulatory I-domain, which radiates to
the pore to control channel gating (George et al., 2004). In turn, the
movement of the I-domainmay be regulated by modulator interactions
with and within the zipper domain (Ikemoto & Yamamoto, 2002; Oda
et al., 2005). These couldbealteredbyphosphorylation,whichpromotes
an allosteric change in the molecule affecting the afﬁnity for FKBP12.6.
Loosening thehold that FKBP12.6 has onRyR2maybepart of thenormal
ﬂight orﬁght response (Jones et al., 2006;Wehrens et al., 2006). Perturb
one of these molecular domain interactions by mutation and in the
presence of phosphorylation the knock-on effect might be increased
sensitivity to luminal or activator Ca2+, for example. As the pore opens
(maybe like the opening of the iris of a camera (Serysheva et al., 1999))
perhaps sites sensitive to luminal Ca2+ are revealed (Jiang et al., 2005).
As discussed, in Section 3.1, one of the many unknowns in RyR channel
gating is how the four subunits of RyR2work together and thismay be a
particularly important consideration in CPVT1 patients where the
genotype is heterozygous and it might be expected that the resultant
RyR2 tetramerswill also be heterologous. How they function together is
a disconcerting gap in our understanding of RyR structure/function and
interpretation and interpolation of ﬁndings to the disease state.
Is RyR2 function and the inherent instability of CICR the ‘Achilles'
heel’ of ECC? Indeed, in HF, because it is such a pivotal protein in ECC,
acting as a regulator and coincidence detector of cellular events, RyR2
is buffeted by every type of stressful change encountered by the
myocyte and in microcosm may merely reﬂect the myocyte's malaise.
When faced with a chaotically regulated environment or wounded by
a point mutation this magniﬁcently robust protein may ﬁnally run out
of possibilities to autoregulate coherently, when assaulted by
phosphorylation. This might explain why broad spectrum strategies
to rescue the myocyte such as β-blockade are successful in HF because
they ‘treat’ ECC as a whole and partially successful in CPVT where
phosphorylation maybe the trigger to arrhythmia.
Despite the intense spotlight on hyperphosphorylation and loss of
FKBP12.6, this has not led to any real understanding of the relationship
between RyR1/2 and FKBP12/12.6 or phosphorylation, in the context of
the normal ﬂight or ﬁght response or the regulation of domain
interactions in normal RyR2. In fact the molecular mechanism by
which phosphorylation changes RyR2 function is uncertain and the
experimental ﬁnding contradictory (see Section 2.4). The reasons why
PP1 and PP2A are speciﬁcally lost from the RyR2 complexwhen they are
present in the remainder of the cell in HF needs further investigation.
Possibilities include changes in the association of their speciﬁc
anchoring proteins for either the phosphatases or RyR2 or changes in
their expression levels and understanding this mechanismmight reveal
a speciﬁc and novel therapeutic target for HF (Hulme et al., 2004). In
CPVT any hesitancy in RyR2's molecular movement may be sufﬁcient to
desynchronise the normal open/closed molecular organisation and
cause arrhythmia. Again there is little appreciation of themechanismby
which phosphorylation unmasks this instability. Preventing arrhythmia
in CPVT may require a direct therapeutic regulation of RyR2 molecular
activity— Ehrlich's ‘magic bullet’ (see Section 5.3.2.3).
The correction of RyR2 dysfunction in both point mutation carriers
and HF patients and the development of novel therapeutic strategies is
currently the focus of a much effort, particularly methods to prevent
the onset of fatal arrhythmia. The efﬁcacy of current and new
therapeutic approaches is, in turn, providing valuable information
on the underlying molecular mechanisms regulating RyR2 channel
gating and function. In the ﬁnal analysis, the pathological changes in
RyR2 which cause spontaneous diastolic leak and arrhythmia must be
understood from a perspective which correlates the dynamics of RyR2
channel gating with intramolecular movement, and this presents an
intriguing challenge.
170 L.M. Blayney, F.A. Lai / Pharmacology & Therapeutics 123 (2009) 151–177A third knock-in mouse model of CPVT has been reported for the
central domain P2328S mutation. Comparison of WT, RyRS/P and
RyRS/S genotypes demonstrated that gene dosage of the mutation
increased the propensity to arrhythmia in myocytes and Langendorff
heart preparations, particularly on the addition of isoproterenol. The
physiological characteristics of CPVT were similar to the two models
described in Section 4.2.2 describing C-terminal and N-terminal CPVT
mutations (Goddard, C. A. et al. (2008). Physiological consequences of
the P2328S mutation in the ryanodine receptor (RyR2) gene in
genetically modiﬁed murine hearts. Acta Physiol (Oxf) 194, 123–140).
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